uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q34.481 | Q34 | What are the names of the genes that are targeted by the drug Dextroamphetamine in the treatment of drug dependence? | In the context of drug dependence, the drug Dextroamphetamine targets the gene solute carrier family 6 member 2, solute carrier family 18 member A2 and solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%drug dependence%" OR LOWER(efo_term) LIKE "%drug dependence%") AND (LOWER(drugName) LIKE "%dextroamphetamine%" OR LOWER(tradeNames_list) LIKE "%dextroamphetamine%" OR LOWER(syns_list) LIKE "%dextroamphetamine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_418425', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418464', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418477', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418490', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418516', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418529', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418542', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418568', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418581', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418594', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418607', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418633', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418646', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418659', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418672', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418685', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418698', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418711', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418724', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418737', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418750', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418776', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418789', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418802', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418815', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418828', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418854', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418867', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418880', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418893', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418906', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418919', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418932', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418945', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418958', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418971', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418984', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418997', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419010', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419023', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419036', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419049', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419062', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419075', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419088', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419101', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419114', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419127', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418763', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418555', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418451', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418399', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418373', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418360', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418841', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418620', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418503', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418438', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418412', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418386', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1006 | Q34 | What are the names of the genes that are targeted by the drug Ipratropium Bromide in the treatment of Nasal congestion? | In the context of Nasal congestion, the drug Ipratropium Bromide targets the gene cholinergic receptor muscarinic 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nasal congestion%" OR LOWER(efo_term) LIKE "%nasal congestion%") AND (LOWER(drugName) LIKE "%ipratropium bromide%" OR LOWER(tradeNames_list) LIKE "%ipratropium bromide%" OR LOWER(syns_list) LIKE "%ipratropium bromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857472', 'drugName': 'Ipratropium Bromide', 'tradeNames_list': "['Atrovent', 'Atrovent aerocaps', 'Atrovent fte', 'Atrovent hfaAtrovent udvs', 'Ipratrop', 'Ipratrop steripoule', 'Ipratropium bromideRespontin', 'Rinatec', 'Tropiovent']", 'syns_list': "['Ipratropium bromide', 'Ipratropium bromide anhydrousIpratropium bromide hydrate', 'Ipratropium bromide monohydrateNSC-759613', 'SCH 1000-BR-MONOHYDRATE', 'SCH-1000-BR-']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.673 | Q34 | What are the names of the genes that are targeted by the drug Apremilast in the treatment of psoriatic arthritis? | In the context of psoriatic arthritis, the drug Apremilast targets the gene phosphodiesterase 4A, phosphodiesterase 4D, phosphodiesterase 4B and phosphodiesterase 4C. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psoriatic arthritis%" OR LOWER(efo_term) LIKE "%psoriatic arthritis%") AND (LOWER(drugName) LIKE "%apremilast%" OR LOWER(tradeNames_list) LIKE "%apremilast%" OR LOWER(syns_list) LIKE "%apremilast%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_696934', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697018', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697046', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697074', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697130', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697158', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697186', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697242', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697270', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697298', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697326', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697382', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697410', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697438', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697466', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697494', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697522', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697550', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697578', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697606', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697634', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697690', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697718', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697746', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697774', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697802', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697858', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697886', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697914', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697942', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697970', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697998', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698026', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698054', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698082', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698110', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698138', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698166', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698194', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698222', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698250', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698278', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698306', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698334', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698362', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698390', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698418', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698446', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698474', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698502', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698530', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698586', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698614', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698642', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698670', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698698', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698726', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698782', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698810', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698838', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698866', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698894', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698922', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698950', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698978', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699006', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699034', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699062', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699090', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699118', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699146', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699174', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699202', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699230', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699258', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699286', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699314', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699342', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699370', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699398', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699426', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699454', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699482', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699510', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699538', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699566', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_698558', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697662', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697214', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696990', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696878', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696822', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696794', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698754', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697830', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697354', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697102', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696962', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696906', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696850', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1363 | Q34 | What are the names of the genes that are targeted by the drug Ibrutinib in the treatment of neoplasm? | In the context of neoplasm, the drug Ibrutinib targets the gene Bruton tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%ibrutinib%" OR LOWER(tradeNames_list) LIKE "%ibrutinib%" OR LOWER(syns_list) LIKE "%ibrutinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_996322', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995033', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995586', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995677', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995816', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997149', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995264', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995494', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995540', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995079', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996138', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996230', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995723', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997058', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997011', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996321', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995815', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997195', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995125', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996459', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995862', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995907', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995954', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995310', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996598', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995999', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995171', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996782', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995080', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996091', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996137', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996828', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995402', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996183', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996229', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997104', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995217', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997057', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997012', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997103', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995769', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996368', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996367', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997241', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996413', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997150', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995263', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997196', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995126', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996460', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995861', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995448', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996275', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995908', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996552', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995309', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996551', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996690', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995539', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996046', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996000', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996689', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996045', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996644', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995355', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996920', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995172', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995632', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995585', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996781', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995631', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996736', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996092', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996919', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995401', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996827', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995724', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996874', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995678', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996873', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996184', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997242', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995770', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996505', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995447', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997288', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997287', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996965', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996735', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996597', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996506', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995953', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995218', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995493', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996643', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995034', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996966', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996414', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995356', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996276', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1854 | Q34 | What are the names of the genes that are targeted by the drug Rosuvastatin Calcium in the treatment of coronary artery disease? | In the context of coronary artery disease, the drug Rosuvastatin Calcium targets the gene 3-hydroxy-3-methylglutaryl-CoA reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%coronary artery disease%" OR LOWER(efo_term) LIKE "%coronary artery disease%") AND (LOWER(drugName) LIKE "%rosuvastatin calcium%" OR LOWER(tradeNames_list) LIKE "%rosuvastatin calcium%" OR LOWER(syns_list) LIKE "%rosuvastatin calcium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1104216', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104250', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104182', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104148', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104131', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104233', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104199', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104165', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1284 | Q34 | What are the names of the genes that are targeted by the drug Pralsetinib in the treatment of medullary thyroid gland carcinoma? | In the context of medullary thyroid gland carcinoma, the drug Pralsetinib targets the gene ret proto-oncogene, coiled-coil domain containing 6 and kinesin family member 5B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%medullary thyroid gland carcinoma%" OR LOWER(efo_term) LIKE "%medullary thyroid gland carcinoma%") AND (LOWER(drugName) LIKE "%pralsetinib%" OR LOWER(tradeNames_list) LIKE "%pralsetinib%" OR LOWER(syns_list) LIKE "%pralsetinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_944314', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944326', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944330', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944334', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944342', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'CCDC6', 'approvedName': 'coiled-coil domain containing 6'}, {'UUID': 'DrugTargetsIndication121923_text_944346', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'CCDC6', 'approvedName': 'coiled-coil domain containing 6'}, {'UUID': 'DrugTargetsIndication121923_text_944350', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'CCDC6', 'approvedName': 'coiled-coil domain containing 6'}, {'UUID': 'DrugTargetsIndication121923_text_944358', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'KIF5B', 'approvedName': 'kinesin family member 5B'}, {'UUID': 'DrugTargetsIndication121923_text_944362', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'KIF5B', 'approvedName': 'kinesin family member 5B'}, {'UUID': 'DrugTargetsIndication121923_text_944366', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'KIF5B', 'approvedName': 'kinesin family member 5B'}, {'UUID': 'DrugTargetsIndication121923_text_944370', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'KIF5B', 'approvedName': 'kinesin family member 5B'}, {'UUID': 'DrugTargetsIndication121923_text_944322', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944306', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944298', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944294', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944354', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'CCDC6', 'approvedName': 'coiled-coil domain containing 6'}, {'UUID': 'DrugTargetsIndication121923_text_944338', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944318', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944310', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944302', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.451 | Q34 | What are the names of the genes that are targeted by the drug Epinephrine in the treatment of muscle cramp? | In the context of muscle cramp, the drug Epinephrine targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D, adrenoceptor alpha 1B, adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%muscle cramp%" OR LOWER(efo_term) LIKE "%muscle cramp%") AND (LOWER(drugName) LIKE "%epinephrine%" OR LOWER(tradeNames_list) LIKE "%epinephrine%" OR LOWER(syns_list) LIKE "%epinephrine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_361098', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361257', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361310', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361363', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361469', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361522', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361575', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361681', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361734', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361787', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361840', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361946', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361999', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362052', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362105', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362158', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362211', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362264', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362317', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362370', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362423', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362529', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362582', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362635', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362688', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362741', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362847', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362900', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362953', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363006', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363059', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363112', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363165', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363218', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363271', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363324', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363377', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363430', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363483', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363536', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363589', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363642', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363695', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363748', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363801', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363854', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363907', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363960', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364013', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364066', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364119', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364225', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364278', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364331', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364384', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364437', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364490', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364596', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364649', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364702', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364755', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364808', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364861', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364914', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364967', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365020', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365073', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365126', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365179', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365232', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365285', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365338', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365391', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365444', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365497', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365550', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365603', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365656', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365709', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365762', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365815', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365868', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365921', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365974', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366027', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366080', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364172', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362476', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361628', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361204', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360992', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360886', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360833', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364543', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362794', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361893', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361416', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361151', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361045', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360939', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1736 | Q34 | What are the names of the genes that are targeted by the drug Patisiran Sodium in the treatment of familial amyloid neuropathy? | In the context of familial amyloid neuropathy, the drug Patisiran Sodium targets the gene transthyretin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%familial amyloid neuropathy%" OR LOWER(efo_term) LIKE "%familial amyloid neuropathy%") AND (LOWER(drugName) LIKE "%patisiran sodium%" OR LOWER(tradeNames_list) LIKE "%patisiran sodium%" OR LOWER(syns_list) LIKE "%patisiran sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097699', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097708', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097711', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097714', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097720', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097723', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097726', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097729', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097705', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097693', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097687', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097684', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097717', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097702', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097696', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097690', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.180 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of pemphigus vulgaris? | In the context of pemphigus vulgaris, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pemphigus vulgaris%" OR LOWER(efo_term) LIKE "%pemphigus vulgaris%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218686', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219310', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219518', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219726', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220142', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220350', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220558', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220766', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219102', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218270', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217854', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217646', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219934', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218894', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218478', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218062', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.393 | Q34 | What are the names of the genes that are targeted by the drug Fluocinolone Acetonide in the treatment of freckles? | In the context of freckles, the drug Fluocinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%freckles%" OR LOWER(efo_term) LIKE "%freckles%") AND (LOWER(drugName) LIKE "%fluocinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%fluocinolone acetonide%" OR LOWER(syns_list) LIKE "%fluocinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_242236', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'syns_list': "['Flucinolone acetonide', 'Fluocinolide (acetate)', 'FluocinoloneFluocinolone acetonide', 'NSC-92339', 'Oto-synalar']", 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanosis', 'efo_term': 'freckles', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242252', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'syns_list': "['Flucinolone acetonide', 'Fluocinolide (acetate)', 'FluocinoloneFluocinolone acetonide', 'NSC-92339', 'Oto-synalar']", 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanosis', 'efo_term': 'freckles', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.582 | Q34 | What are the names of the genes that are targeted by the drug Lidocaine in the treatment of postherpetic neuralgia? | In the context of postherpetic neuralgia, the drug Lidocaine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%postherpetic neuralgia%" OR LOWER(efo_term) LIKE "%postherpetic neuralgia%") AND (LOWER(drugName) LIKE "%lidocaine%" OR LOWER(tradeNames_list) LIKE "%lidocaine%" OR LOWER(syns_list) LIKE "%lidocaine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_638372', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638717', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638832', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638947', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639177', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639292', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639407', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639637', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639752', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639867', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639982', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640212', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640327', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640442', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640557', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640672', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640787', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640902', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641017', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641132', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641247', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641477', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641592', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641707', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641822', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641937', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642167', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642282', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642397', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642512', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642627', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642742', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642857', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642972', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643087', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643202', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643317', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643432', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643547', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643662', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643777', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643892', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_644007', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644122', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644237', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644352', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644467', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644582', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_641362', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639522', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638602', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638142', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637912', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637797', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_642052', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_640097', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639062', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638487', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638257', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638027', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1747 | Q34 | What are the names of the genes that are targeted by the drug Esomeprazole Magnesium in the treatment of duodenal ulcer? | In the context of duodenal ulcer, the drug Esomeprazole Magnesium targets the gene ATPase H+/K+ transporting subunit alpha and ATPase H+/K+ transporting subunit beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%duodenal ulcer%" OR LOWER(efo_term) LIKE "%duodenal ulcer%") AND (LOWER(drugName) LIKE "%esomeprazole magnesium%" OR LOWER(tradeNames_list) LIKE "%esomeprazole magnesium%" OR LOWER(syns_list) LIKE "%esomeprazole magnesium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097874', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097862', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097898', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097886', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1692 | Q34 | What are the names of the genes that are targeted by the drug Goserelin Acetate in the treatment of breast cancer? | In the context of breast cancer, the drug Goserelin Acetate targets the gene gonadotropin releasing hormone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast cancer%" OR LOWER(efo_term) LIKE "%breast cancer%") AND (LOWER(drugName) LIKE "%goserelin acetate%" OR LOWER(tradeNames_list) LIKE "%goserelin acetate%" OR LOWER(syns_list) LIKE "%goserelin acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1096871', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096843', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096829', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096857', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'syns_list': "['Fertilan', 'Goserelin Acetate', 'Goserelin acetate']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096937', 'drugName': 'Goserelin', 'tradeNames_list': "['Zoladex']", 'syns_list': "['Goserelin', 'Goserelin acetate', 'ICI 118,630', 'ICI-118630']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096903', 'drugName': 'Goserelin', 'tradeNames_list': "['Zoladex']", 'syns_list': "['Goserelin', 'Goserelin acetate', 'ICI 118,630', 'ICI-118630']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096886', 'drugName': 'Goserelin', 'tradeNames_list': "['Zoladex']", 'syns_list': "['Goserelin', 'Goserelin acetate', 'ICI 118,630', 'ICI-118630']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096920', 'drugName': 'Goserelin', 'tradeNames_list': "['Zoladex']", 'syns_list': "['Goserelin', 'Goserelin acetate', 'ICI 118,630', 'ICI-118630']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1273 | Q34 | What are the names of the genes that are targeted by the drug Irinotecan Hydrochloride in the treatment of adenocarcinoma? | In the context of adenocarcinoma, the drug Irinotecan Hydrochloride targets the gene DNA topoisomerase I. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%adenocarcinoma%" OR LOWER(efo_term) LIKE "%adenocarcinoma%") AND (LOWER(drugName) LIKE "%irinotecan hydrochloride%" OR LOWER(tradeNames_list) LIKE "%irinotecan hydrochloride%" OR LOWER(syns_list) LIKE "%irinotecan hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_942399', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941599', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940999', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942599', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940799', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941899', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940699', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942499', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941299', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941399', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941999', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940899', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941099', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942099', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941199', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941699', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942299', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941499', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942199', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941799', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenocarcinoma', 'efo_term': 'adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940983', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941285', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941288', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942185', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941585', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942485', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941885', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941388', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942085', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941385', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941985', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941983', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941888', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941383', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942083', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940885', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941683', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941183', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941685', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941688', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940783', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940683', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941788', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941785', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940788', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941988', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942088', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941588', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942183', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941783', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942188', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941483', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940888', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941088', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942483', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941583', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941085', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942285', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942588', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941185', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941188', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940688', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942583', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942585', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942488', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941485', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940785', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942288', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942283', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941083', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940883', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940685', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942383', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941488', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942385', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_942388', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941283', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_941883', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940985', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}, {'UUID': 'DrugTargetsIndication121923_text_940988', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_list': "['Campto', 'Camptosar', 'Irinotecan hydrochloride', 'Onivyde']", 'syns_list': "['CPT-11', 'DQ-2805', 'Irinotecan hydrochlorideIrinotecan hydrochloride anhydrous', 'Irinotecan hydrochloride hydrateIrinotecan hydrochloride trihydrateIrinotecan monohydrochloride trihydrate', 'NSC-759878', 'U-101,440EU-101440E']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'TOP1', 'approvedName': 'DNA topoisomerase I'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1630 | Q34 | What are the names of the genes that are targeted by the drug Dabigatran in the treatment of CADASIL? | Dabigatran has not been approved by the FDA as a treatment for CADASIL, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target name is coagulation factor II, thrombin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cadasil%" OR LOWER(efo_term) LIKE "%cadasil%") AND (LOWER(drugName) LIKE "%dabigatran%" OR LOWER(tradeNames_list) LIKE "%dabigatran%" OR LOWER(syns_list) LIKE "%dabigatran%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1093463', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093496', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093507', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093518', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093540', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093551', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093562', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093584', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093595', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093606', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093617', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093639', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093650', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093661', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093672', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093683', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093694', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093705', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093716', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093727', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093738', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093760', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093771', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093782', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093793', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093804', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093826', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093837', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093848', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093859', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093870', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093881', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093892', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093903', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093914', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093925', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093936', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093947', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093958', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093969', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093980', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093991', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1094002', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1094013', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1094024', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093749', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093573', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093485', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093441', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093419', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093408', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093815', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093628', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093529', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093474', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093452', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093430', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'CADASIL', 'efo_term': 'CADASIL', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1441 | Q34 | What are the names of the genes that are targeted by the drug Amlodipine Benzoate in the treatment of stroke? | In the context of stroke, the drug Amlodipine Benzoate targets the gene calcium voltage-gated channel subunit alpha1 C, calcium voltage-gated channel subunit alpha1 S, calcium voltage-gated channel subunit alpha1 D and calcium voltage-gated channel subunit alpha1 F. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%stroke%" OR LOWER(efo_term) LIKE "%stroke%") AND (LOWER(drugName) LIKE "%amlodipine benzoate%" OR LOWER(tradeNames_list) LIKE "%amlodipine benzoate%" OR LOWER(syns_list) LIKE "%amlodipine benzoate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1044028', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044046', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044052', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044058', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044070', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044076', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044082', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044094', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044100', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044106', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044112', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044124', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044130', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044136', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044142', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044148', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044154', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044160', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044166', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044172', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044178', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044184', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044088', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044040', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044016', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044004', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043998', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044118', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044064', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044034', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044022', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044010', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.826 | Q34 | What are the names of the genes that are targeted by the drug Acetaminophen in the treatment of Headache? | In the context of Headache, the drug Acetaminophen targets the gene prostaglandin-endoperoxide synthase 2, prostaglandin-endoperoxide synthase 1, transient receptor potential cation channel subfamily V member 1 and fatty acid amide hydrolase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%headache%" OR LOWER(efo_term) LIKE "%headache%") AND (LOWER(drugName) LIKE "%acetaminophen%" OR LOWER(tradeNames_list) LIKE "%acetaminophen%" OR LOWER(syns_list) LIKE "%acetaminophen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_830307', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_831147', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_828942', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830937', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831357', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_828732', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829992', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829047', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829782', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_831882', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_829467', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_831672', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_832512', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_830202', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830832', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_830727', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830517', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829152', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829257', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829362', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832092', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_831567', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_832407', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832197', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832302', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_831777', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_830412', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828837', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829677', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_831987', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832722', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_829887', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_831042', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_832617', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_831252', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_830622', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830097', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_832827', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_829572', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_831462', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829710', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830760', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_830865', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829815', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830970', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831075', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829290', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829920', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_831180', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_828765', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_831285', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_830025', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_831390', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831495', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831915', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_828975', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830130', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829185', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_831600', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831705', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_828660', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829395', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829080', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829500', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830340', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_832125', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_830445', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_832230', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832020', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832335', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_829605', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830550', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_832440', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_828870', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832545', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_830655', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_832650', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832755', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_831810', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_830235', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1000 | Q34 | What are the names of the genes that are targeted by the drug Umeclidinium Bromide in the treatment of chronic bronchitis? | In the context of chronic bronchitis, the drug Umeclidinium Bromide targets the gene cholinergic receptor muscarinic 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic bronchitis%" OR LOWER(efo_term) LIKE "%chronic bronchitis%") AND (LOWER(drugName) LIKE "%umeclidinium bromide%" OR LOWER(tradeNames_list) LIKE "%umeclidinium bromide%" OR LOWER(syns_list) LIKE "%umeclidinium bromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857417', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857432', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857437', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857427', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857397', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857392', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857407', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857422', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857412', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857402', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.949 | Q34 | What are the names of the genes that are targeted by the drug Diclofenac Epolamine in the treatment of pain? | In the context of pain, the drug Diclofenac Epolamine targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%diclofenac epolamine%" OR LOWER(tradeNames_list) LIKE "%diclofenac epolamine%" OR LOWER(syns_list) LIKE "%diclofenac epolamine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_842275', 'drugName': 'Diclofenac Epolamine', 'tradeNames_list': "['Flector', 'Flector Patch', 'Licart']", 'syns_list': "['Diclofenac epolamine', 'Diclofenac epolaminum']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842271', 'drugName': 'Diclofenac Epolamine', 'tradeNames_list': "['Flector', 'Flector Patch', 'Licart']", 'syns_list': "['Diclofenac epolamine', 'Diclofenac epolaminum']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842283', 'drugName': 'Diclofenac Epolamine', 'tradeNames_list': "['Flector', 'Flector Patch', 'Licart']", 'syns_list': "['Diclofenac epolamine', 'Diclofenac epolaminum']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842279', 'drugName': 'Diclofenac Epolamine', 'tradeNames_list': "['Flector', 'Flector Patch', 'Licart']", 'syns_list': "['Diclofenac epolamine', 'Diclofenac epolaminum']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1895 | Q34 | What are the names of the genes that are targeted by the drug Torsemide in the treatment of heart failure? | In the context of heart failure, the drug Torsemide targets the gene solute carrier family 12 member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%heart failure%" OR LOWER(efo_term) LIKE "%heart failure%") AND (LOWER(drugName) LIKE "%torsemide%" OR LOWER(tradeNames_list) LIKE "%torsemide%" OR LOWER(syns_list) LIKE "%torsemide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149093', 'drugName': 'Torsemide', 'tradeNames_list': "['Demadex', 'Soaanz', 'Torem 10', 'Torem 2.5', 'Torem 5', 'Torsemide']", 'syns_list': "['AC-4464', 'AC4464', 'BM-02.015', 'BM-02015', 'BM02.015', 'LupracTorasemide', 'Torasemide anhydrous', 'Torsemide', 'Upcard']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC12A1', 'approvedName': 'solute carrier family 12 member 1'}, {'UUID': 'DrugTargetsIndication121923_text_1149089', 'drugName': 'Torsemide', 'tradeNames_list': "['Demadex', 'Soaanz', 'Torem 10', 'Torem 2.5', 'Torem 5', 'Torsemide']", 'syns_list': "['AC-4464', 'AC4464', 'BM-02.015', 'BM-02015', 'BM02.015', 'LupracTorasemide', 'Torasemide anhydrous', 'Torsemide', 'Upcard']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'SLC12A1', 'approvedName': 'solute carrier family 12 member 1'}, {'UUID': 'DrugTargetsIndication121923_text_1149101', 'drugName': 'Torsemide', 'tradeNames_list': "['Demadex', 'Soaanz', 'Torem 10', 'Torem 2.5', 'Torem 5', 'Torsemide']", 'syns_list': "['AC-4464', 'AC4464', 'BM-02.015', 'BM-02015', 'BM02.015', 'LupracTorasemide', 'Torasemide anhydrous', 'Torsemide', 'Upcard']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC12A1', 'approvedName': 'solute carrier family 12 member 1'}, {'UUID': 'DrugTargetsIndication121923_text_1149097', 'drugName': 'Torsemide', 'tradeNames_list': "['Demadex', 'Soaanz', 'Torem 10', 'Torem 2.5', 'Torem 5', 'Torsemide']", 'syns_list': "['AC-4464', 'AC4464', 'BM-02.015', 'BM-02015', 'BM02.015', 'LupracTorasemide', 'Torasemide anhydrous', 'Torsemide', 'Upcard']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'SLC12A1', 'approvedName': 'solute carrier family 12 member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.669 | Q34 | What are the names of the genes that are targeted by the drug Crisaborole in the treatment of atopic eczema? | In the context of atopic eczema, the drug Crisaborole targets the gene phosphodiesterase 4A, phosphodiesterase 4D, phosphodiesterase 4B and phosphodiesterase 4C. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%atopic eczema%" OR LOWER(efo_term) LIKE "%atopic eczema%") AND (LOWER(drugName) LIKE "%crisaborole%" OR LOWER(tradeNames_list) LIKE "%crisaborole%" OR LOWER(syns_list) LIKE "%crisaborole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_696585', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696606', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_696613', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_696620', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_696634', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_696641', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_696648', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_696662', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696669', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696676', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696683', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696697', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696704', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696711', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696718', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696725', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696732', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696739', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696746', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696753', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696760', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696767', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696655', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_696599', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696571', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696557', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696550', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696690', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696627', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_696592', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696578', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696564', 'drugName': 'Crisaborole', 'tradeNames_list': "['Eucrisa']", 'syns_list': "['AN-2728', 'AN2728', 'Crisaborole']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.144 | Q34 | What are the names of the genes that are targeted by the drug Lapatinib Ditosylate in the treatment of breast carcinoma? | In the context of breast carcinoma, the drug Lapatinib Ditosylate targets the gene epidermal growth factor receptor and erb-b2 receptor tyrosine kinase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast carcinoma%" OR LOWER(efo_term) LIKE "%breast carcinoma%") AND (LOWER(drugName) LIKE "%lapatinib ditosylate%" OR LOWER(tradeNames_list) LIKE "%lapatinib ditosylate%" OR LOWER(syns_list) LIKE "%lapatinib ditosylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217425', 'drugName': 'Lapatinib Ditosylate', 'tradeNames_list': "['Tykerb']", 'syns_list': "['GW-572016F', 'GW572016F', 'LapatinibLapatinib ditoluenesulfonate monohydrate', 'Lapatinib ditosylateLapatinib ditosylate anhydrous', 'Lapatinib ditosylate monohydrateLapatinib tosilate', 'Lapatinib tosilate hydrate', 'Tycerb']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_217407', 'drugName': 'Lapatinib Ditosylate', 'tradeNames_list': "['Tykerb']", 'syns_list': "['GW-572016F', 'GW572016F', 'LapatinibLapatinib ditoluenesulfonate monohydrate', 'Lapatinib ditosylateLapatinib ditosylate anhydrous', 'Lapatinib ditosylate monohydrateLapatinib tosilate', 'Lapatinib tosilate hydrate', 'Tycerb']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217406', 'drugName': 'Lapatinib Ditosylate', 'tradeNames_list': "['Tykerb']", 'syns_list': "['GW-572016F', 'GW572016F', 'LapatinibLapatinib ditoluenesulfonate monohydrate', 'Lapatinib ditosylateLapatinib ditosylate anhydrous', 'Lapatinib ditosylate monohydrateLapatinib tosilate', 'Lapatinib tosilate hydrate', 'Tycerb']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217424', 'drugName': 'Lapatinib Ditosylate', 'tradeNames_list': "['Tykerb']", 'syns_list': "['GW-572016F', 'GW572016F', 'LapatinibLapatinib ditoluenesulfonate monohydrate', 'Lapatinib ditosylateLapatinib ditosylate anhydrous', 'Lapatinib ditosylate monohydrateLapatinib tosilate', 'Lapatinib tosilate hydrate', 'Tycerb']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1503 | Q34 | What are the names of the genes that are targeted by the drug Pralatrexate in the treatment of unspecified peripheral T-cell lymphoma? | In the context of unspecified peripheral T-cell lymphoma, the drug Pralatrexate targets the gene dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%unspecified peripheral t-cell lymphoma%" OR LOWER(efo_term) LIKE "%unspecified peripheral t-cell lymphoma%") AND (LOWER(drugName) LIKE "%pralatrexate%" OR LOWER(tradeNames_list) LIKE "%pralatrexate%" OR LOWER(syns_list) LIKE "%pralatrexate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072532', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072456', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072437', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072494', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072513', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072475', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1414 | Q34 | What are the names of the genes that are targeted by the drug Doxycycline in the treatment of Tularemia? | In the context of Tularemia, the drug Doxycycline targets the gene matrix metallopeptidase 7, matrix metallopeptidase 1, matrix metallopeptidase 13 and matrix metallopeptidase 8. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%tularemia%" OR LOWER(efo_term) LIKE "%tularemia%") AND (LOWER(drugName) LIKE "%doxycycline%" OR LOWER(tradeNames_list) LIKE "%doxycycline%" OR LOWER(syns_list) LIKE "%doxycycline%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1038228', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038453', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038528', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038603', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038753', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038828', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038903', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039053', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039128', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039203', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039278', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039428', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039503', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039578', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039653', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039728', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039803', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039878', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039953', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040028', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040103', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040253', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040328', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040403', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040478', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040553', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040703', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040778', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040853', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040928', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1041003', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1041078', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040178', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1038978', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038378', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038078', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037928', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037853', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1040628', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1039353', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038678', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038303', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038153', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038003', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.424 | Q34 | What are the names of the genes that are targeted by the drug Treprostinil in the treatment of Recurrent thrombophlebitis? | In the context of Recurrent thrombophlebitis, the drug Treprostinil targets the gene prostaglandin I2 receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%recurrent thrombophlebitis%" OR LOWER(efo_term) LIKE "%recurrent thrombophlebitis%") AND (LOWER(drugName) LIKE "%treprostinil%" OR LOWER(tradeNames_list) LIKE "%treprostinil%" OR LOWER(syns_list) LIKE "%treprostinil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_244533', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244584', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244601', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244618', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244652', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244669', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244686', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244720', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244737', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244754', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244771', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244805', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244822', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244839', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244856', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244873', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244890', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244907', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244924', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244941', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244958', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244992', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245009', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245026', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245043', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245060', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245094', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245111', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245128', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245145', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245162', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245179', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245196', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245213', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245230', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245247', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245264', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245281', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245298', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245315', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245332', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245349', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245366', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245383', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245400', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245417', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245434', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245451', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245468', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245485', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245502', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245536', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245553', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245570', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245587', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245604', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245621', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245655', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245672', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245689', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245706', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245723', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245740', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245757', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245774', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245791', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245808', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245825', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245842', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245859', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245876', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245893', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245910', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245927', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245944', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245961', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245978', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245519', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244975', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244703', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244567', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244499', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244465', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244448', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245638', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245077', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244788', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244635', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244550', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244516', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244482', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.641 | Q34 | What are the names of the genes that are targeted by the drug Lenvatinib Mesylate in the treatment of renal cell carcinoma? | In the context of renal cell carcinoma, the drug Lenvatinib Mesylate targets the gene kinase insert domain receptor, fms related receptor tyrosine kinase 1 and fms related receptor tyrosine kinase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%renal cell carcinoma%" OR LOWER(efo_term) LIKE "%renal cell carcinoma%") AND (LOWER(drugName) LIKE "%lenvatinib mesylate%" OR LOWER(tradeNames_list) LIKE "%lenvatinib mesylate%" OR LOWER(syns_list) LIKE "%lenvatinib mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_690182', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690212', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690222', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690232', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690252', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690262', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690272', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690292', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690302', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690312', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690322', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690342', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690352', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690362', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690372', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690382', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690392', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690402', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690412', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690422', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690432', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690452', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690462', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690472', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690482', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690442', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690202', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690162', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690142', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690132', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690282', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690332', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690242', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690192', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690172', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690152', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1391 | Q34 | What are the names of the genes that are targeted by the drug Brimonidine Tartrate in the treatment of ocular hypertension? | In the context of ocular hypertension, the drug Brimonidine Tartrate targets the gene adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ocular hypertension%" OR LOWER(efo_term) LIKE "%ocular hypertension%") AND (LOWER(drugName) LIKE "%brimonidine tartrate%" OR LOWER(tradeNames_list) LIKE "%brimonidine tartrate%" OR LOWER(syns_list) LIKE "%brimonidine tartrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1034086', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034115', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034116', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034130', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034145', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034146', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034160', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034175', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034176', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034190', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034191', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034206', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034220', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034221', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034235', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034236', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034250', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034251', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034265', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034266', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034280', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034295', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034296', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034310', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034311', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034325', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034340', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034341', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034355', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034356', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034370', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034371', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034385', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034386', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034400', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034401', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034415', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034416', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034430', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034431', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034445', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034446', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034460', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034461', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034475', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034476', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034490', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034491', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034505', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034506', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034520', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034535', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034536', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034550', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034551', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034565', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034566', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034581', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034595', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034596', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034610', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034611', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034625', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034626', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034640', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034641', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034655', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034656', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034670', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034671', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034685', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034686', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034700', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034701', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034715', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034716', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034730', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034731', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034745', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034746', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034760', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034761', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034775', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034776', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034790', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034791', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034521', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034281', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034161', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034101', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034071', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034056', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034055', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034580', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034326', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034205', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034131', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Intraocular Pressure', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034100', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034085', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034070', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.805 | Q34 | What are the names of the genes that are targeted by the drug Estradiol in the treatment of Dyspareunia? | In the context of Dyspareunia, the drug Estradiol targets the gene estrogen receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%dyspareunia%" OR LOWER(efo_term) LIKE "%dyspareunia%") AND (LOWER(drugName) LIKE "%estradiol%" OR LOWER(tradeNames_list) LIKE "%estradiol%" OR LOWER(syns_list) LIKE "%estradiol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_824179', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824329', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824379', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824429', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824529', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824579', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824629', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824729', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824779', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824829', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824879', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824979', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825029', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825079', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825129', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825179', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825229', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825279', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825329', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825379', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825429', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825529', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825579', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825629', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825679', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825729', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825829', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825879', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825929', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825979', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826029', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826079', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826129', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826179', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826229', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826279', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826329', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826379', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826429', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826479', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826529', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826579', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826629', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826679', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826729', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826779', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826829', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826879', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826929', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_826979', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827029', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827129', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827179', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827229', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827279', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827329', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827379', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827479', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827529', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827579', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827629', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827679', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827729', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827779', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827829', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827879', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827929', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827979', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_828029', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827079', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825479', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824679', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824279', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824079', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823979', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823929', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_827429', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_825779', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824929', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824479', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824229', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824129', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_824029', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'syns_list': "['17-.beta.-oestradiol', '17-beta-oestradiol', '17.beta.-estradiol17beta-estradiol', 'Agofollin', 'Alfatradiol', 'Depo-EstradiolDestradiol', 'Dihydrotheelin', 'Dihydroxyestrin', 'EstradiolEstradiol 17-beta', 'Estradiol anhydrous', 'Estradiol hemihydrateEstradiol valerate metabolite e2', 'Estrasorb', 'Gynergon', 'GynoestrylNSC-20293', 'NSC-9895', 'Oestradiol', 'WC-3011', 'WC3011']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1417 | Q34 | What are the names of the genes that are targeted by the drug Pasireotide Pamoate in the treatment of acromegaly? | In the context of acromegaly, the drug Pasireotide Pamoate targets the gene somatostatin receptor 5, somatostatin receptor 2, somatostatin receptor 3 and somatostatin receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%acromegaly%" OR LOWER(efo_term) LIKE "%acromegaly%") AND (LOWER(drugName) LIKE "%pasireotide pamoate%" OR LOWER(tradeNames_list) LIKE "%pasireotide pamoate%" OR LOWER(syns_list) LIKE "%pasireotide pamoate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1041099', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1041102', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1041103', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1041104', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1041106', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1041107', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1041108', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1041110', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1041111', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1041112', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1041113', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1041115', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1041116', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1041117', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1041118', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1041119', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1041120', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1041121', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1041122', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1041123', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1041124', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1041126', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1041127', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1041128', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1041129', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1041130', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1041132', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1041133', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1041134', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1041135', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1041136', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1041137', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1041138', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1041139', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1041140', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1041141', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1041142', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1041143', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1041144', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1041145', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1041146', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1041147', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1041148', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041149', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041150', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041151', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041152', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041153', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041154', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041155', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041156', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041158', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041159', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041160', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041161', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041162', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041163', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041165', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041157', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041125', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1041109', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1041101', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1041097', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1041095', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1041094', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1041164', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041131', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1041114', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1041105', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1041100', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1041098', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1041096', 'drugName': 'Pasireotide Pamoate', 'tradeNames_list': "['Signifor lar', 'Signifor lar kit']", 'syns_list': "['Pasireotide embonate', 'Pasireotide pamoate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.620 | Q34 | What are the names of the genes that are targeted by the drug Nintedanib Esylate in the treatment of idiopathic pulmonary fibrosis? | In the context of idiopathic pulmonary fibrosis, the drug Nintedanib Esylate targets the gene kinase insert domain receptor, fibroblast growth factor receptor 1, fibroblast growth factor receptor 3, fibroblast growth factor receptor 2, fms related receptor tyrosine kinase 1, fms related receptor tyrosine kinase 4, platelet derived growth factor receptor beta, platelet derived growth factor receptor alpha and fibroblast growth factor receptor 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%idiopathic pulmonary fibrosis%" OR LOWER(efo_term) LIKE "%idiopathic pulmonary fibrosis%") AND (LOWER(drugName) LIKE "%nintedanib esylate%" OR LOWER(tradeNames_list) LIKE "%nintedanib esylate%" OR LOWER(syns_list) LIKE "%nintedanib esylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_678478', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678484', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678486', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678488', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_678492', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_678494', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_678496', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_678500', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_678502', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_678504', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_678506', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_678510', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_678512', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_678514', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_678516', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_678518', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_678520', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_678522', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_678524', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_678526', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_678528', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678532', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678534', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678536', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678538', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678540', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678544', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678546', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678548', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_678550', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_678552', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_678554', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_678556', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_678558', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_678560', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_678562', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_678564', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_678566', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_678568', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_678570', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_678572', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_678574', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_678576', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_678578', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_678580', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_678582', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_678584', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_678586', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_678588', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_678590', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_678592', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_678596', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_678598', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_678600', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_678602', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_678604', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_678606', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_678610', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678612', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678614', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678616', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678618', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678620', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678622', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678624', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678626', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678628', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_678630', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_678632', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_678634', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_678636', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_678638', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_678640', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_678642', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_678644', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_678646', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_678594', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_678530', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678498', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_678482', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678474', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678470', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678468', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678608', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678542', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678508', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_678490', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_678480', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678476', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_678472', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'syns_list': "['Nintedanib esilate', 'Nintedanib esylate', 'Nintedanib ethanesulfonate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.296 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of neoplasm? | In the context of neoplasm, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227461', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229171', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229746', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232021', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226326', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228316', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230031', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228886', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229461', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231171', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230311', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231166', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226896', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227181', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228601', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230886', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228891', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227751', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231456', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232306', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230316', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226611', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227176', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228606', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229741', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227746', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230601', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231736', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231741', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226321', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226891', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228031', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232026', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228036', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226606', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230026', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229456', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227466', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232311', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231451', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230881', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228321', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230596', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229176', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227719', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226506', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226281', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226517', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226579', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226578', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226577', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226547', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226532', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227919', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226510', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227660', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226292', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226505', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227433', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227432', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226225', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226520', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226530', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226293', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226790', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226791', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227447', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Female', 'efo_term': 'female reproductive system neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226877', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Female', 'efo_term': 'female reproductive system neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227930', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226863', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226851', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227650', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226817', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226805', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227657', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226232', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226294', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227634', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226802', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227645', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227646', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226815', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226235', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226795', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226832', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226862', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226245', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226864', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226779', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227687', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227718', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227732', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Female', 'efo_term': 'female reproductive system neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227672', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227421', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227706', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227717', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226494', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226262', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Male', 'efo_term': 'male reproductive organ cancer', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226566', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226307', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Genital Neoplasms, Female', 'efo_term': 'female reproductive system neoplasm', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1242 | Q34 | What are the names of the genes that are targeted by the drug Maraviroc in the treatment of HIV-1 infection? | In the context of HIV-1 infection, the drug Maraviroc targets the gene C-C motif chemokine receptor 5. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hiv-1 infection%" OR LOWER(efo_term) LIKE "%hiv-1 infection%") AND (LOWER(drugName) LIKE "%maraviroc%" OR LOWER(tradeNames_list) LIKE "%maraviroc%" OR LOWER(syns_list) LIKE "%maraviroc%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_938389', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938452', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938473', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938494', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938536', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938557', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938578', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938431', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938347', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938305', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938284', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938515', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938410', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938368', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938326', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'syns_list': "['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1321 | Q34 | What are the names of the genes that are targeted by the drug Nitric Oxide in the treatment of respiratory failure? | In the context of respiratory failure, the drug Nitric Oxide targets the gene guanylate cyclase 1 soluble subunit beta 1, guanylate cyclase 1 soluble subunit beta 2 (pseudogene), guanylate cyclase 1 soluble subunit alpha 2 and guanylate cyclase 1 soluble subunit alpha 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%respiratory failure%" OR LOWER(efo_term) LIKE "%respiratory failure%") AND (LOWER(drugName) LIKE "%nitric oxide%" OR LOWER(tradeNames_list) LIKE "%nitric oxide%" OR LOWER(syns_list) LIKE "%nitric oxide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_974424', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974586', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974640', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974694', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974802', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974856', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974910', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975018', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975072', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975126', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975180', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975288', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975342', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975396', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975450', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975504', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975558', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975612', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975666', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975720', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975774', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975882', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975936', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975990', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976044', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976098', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976206', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976260', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976314', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976368', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976422', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976476', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976530', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976584', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976638', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976692', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976746', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976800', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976854', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976908', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976962', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977016', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977070', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977124', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977178', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977232', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977286', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977340', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977394', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977448', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977502', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977610', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977664', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977718', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977772', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977826', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977880', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977988', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_978042', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978096', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978150', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978204', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978258', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978312', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978366', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978420', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978474', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978528', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978582', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978636', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978690', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978744', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978798', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978852', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978906', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978960', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979014', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979068', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979122', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979176', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979230', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979284', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979338', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979392', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979446', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979500', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_977556', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975828', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974964', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974532', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974316', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974208', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974154', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977934', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976152', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975234', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974748', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974478', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974370', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974262', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1884 | Q34 | What are the names of the genes that are targeted by the drug Velcalcetide in the treatment of secondary hyperparathyroidism? | In the context of secondary hyperparathyroidism, the drug Velcalcetide targets the gene calcium sensing receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%secondary hyperparathyroidism%" OR LOWER(efo_term) LIKE "%secondary hyperparathyroidism%") AND (LOWER(drugName) LIKE "%velcalcetide%" OR LOWER(tradeNames_list) LIKE "%velcalcetide%" OR LOWER(syns_list) LIKE "%velcalcetide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1148962', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'syns_list': "['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'TelcalcetideVelcalcetide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1148971', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'syns_list': "['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'TelcalcetideVelcalcetide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1148974', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'syns_list': "['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'TelcalcetideVelcalcetide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1148977', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'syns_list': "['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'TelcalcetideVelcalcetide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1148983', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'syns_list': "['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'TelcalcetideVelcalcetide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1148986', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'syns_list': "['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'TelcalcetideVelcalcetide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1148989', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'syns_list': "['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'TelcalcetideVelcalcetide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1148995', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'syns_list': "['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'TelcalcetideVelcalcetide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1148998', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'syns_list': "['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'TelcalcetideVelcalcetide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149001', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'syns_list': "['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'TelcalcetideVelcalcetide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149004', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'syns_list': "['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'TelcalcetideVelcalcetide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1148992', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'syns_list': "['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'TelcalcetideVelcalcetide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1148968', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'syns_list': "['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'TelcalcetideVelcalcetide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1148956', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'syns_list': "['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'TelcalcetideVelcalcetide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1148950', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'syns_list': "['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'TelcalcetideVelcalcetide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1148947', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'syns_list': "['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'TelcalcetideVelcalcetide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149007', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'syns_list': "['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'TelcalcetideVelcalcetide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1148980', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'syns_list': "['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'TelcalcetideVelcalcetide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1148965', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'syns_list': "['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'TelcalcetideVelcalcetide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1148959', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'syns_list': "['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'TelcalcetideVelcalcetide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1148953', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'syns_list': "['AMG-416', 'Amg416', 'Etelcalcetide', 'KAI-4169', 'ONO-5163', 'TelcalcetideVelcalcetide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperparathyroidism, Secondary', 'efo_term': 'secondary hyperparathyroidism', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.90 | Q34 | What are the names of the genes that are targeted by the drug Vortioxetine Hydrobromide in the treatment of major depressive disorder? | In the context of major depressive disorder, the drug Vortioxetine Hydrobromide targets the gene 5-hydroxytryptamine receptor 3A, solute carrier family 6 member 4 and 5-hydroxytryptamine receptor 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%major depressive disorder%" OR LOWER(efo_term) LIKE "%major depressive disorder%") AND (LOWER(drugName) LIKE "%vortioxetine hydrobromide%" OR LOWER(tradeNames_list) LIKE "%vortioxetine hydrobromide%" OR LOWER(syns_list) LIKE "%vortioxetine hydrobromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205260', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205266', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205268', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205270', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205274', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205276', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205278', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205282', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205284', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205286', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205288', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205292', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205294', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205296', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205298', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205300', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205302', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205304', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205306', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205308', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205310', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205314', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205316', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205318', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205320', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205322', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205326', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205328', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205330', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205332', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205334', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205336', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205338', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205340', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205342', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205344', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205346', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205348', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205350', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205352', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205354', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205356', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205358', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205360', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205362', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205364', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205366', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205368', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205370', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205372', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205374', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205378', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205380', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205382', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205384', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205386', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205388', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205392', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205394', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205396', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205398', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205400', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205402', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205404', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205406', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205408', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205410', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_205412', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_205414', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_205416', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_205418', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_205420', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_205422', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_205424', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_205426', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_205428', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_205430', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_205432', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_205434', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_205436', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_205438', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_205440', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_205442', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_205444', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_205446', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_205448', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR1A', 'approvedName': '5-hydroxytryptamine receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_205376', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205312', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205280', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205264', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205256', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205252', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205250', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205390', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205324', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205290', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205272', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205262', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205258', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205254', 'drugName': 'Vortioxetine Hydrobromide', 'tradeNames_list': "['Trintellix']", 'syns_list': "['Lu AA21004 (HBr)', 'Lu aa21004 hbr', 'Lu-aa21004 hydrobromideVortioxetine hydrobromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.42 | Q34 | What are the names of the genes that are targeted by the drug Aripiprazole in the treatment of psychosis? | In the context of psychosis, the drug Aripiprazole targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 2A and 5-hydroxytryptamine receptor 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psychosis%" OR LOWER(efo_term) LIKE "%psychosis%") AND (LOWER(drugName) LIKE "%aripiprazole%" OR LOWER(tradeNames_list) LIKE "%aripiprazole%" OR LOWER(syns_list) LIKE "%aripiprazole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_159202', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159286', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159314', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159342', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159398', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159426', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159454', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159510', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159538', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159566', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159594', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159650', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159678', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159706', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159734', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159762', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159790', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159818', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159846', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159874', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159902', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159958', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159986', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160014', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160042', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160070', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160126', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160154', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160182', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160210', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160238', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160266', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160294', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160322', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160350', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160378', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160406', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160434', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160462', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160490', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160518', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160546', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160574', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160602', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160630', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160658', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160686', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160714', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160742', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160770', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160798', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160854', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160882', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160910', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160938', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160966', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160994', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161050', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161078', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161106', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161134', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161162', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161190', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161218', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161246', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161274', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161302', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161330', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161358', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161386', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161414', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161442', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161470', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161498', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161526', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161554', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161582', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161610', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161638', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161666', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161694', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161722', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161750', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161778', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161806', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161834', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160826', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159930', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159482', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159258', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159146', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159090', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159062', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161022', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160098', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159622', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159370', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159230', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159174', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159118', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1785 | Q34 | What are the names of the genes that are targeted by the drug Zoledronic Acid in the treatment of bone metastasis? | In the context of bone metastasis, the drug Zoledronic Acid targets the gene farnesyl diphosphate synthase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bone metastasis%" OR LOWER(efo_term) LIKE "%bone metastasis%") AND (LOWER(drugName) LIKE "%zoledronic acid%" OR LOWER(tradeNames_list) LIKE "%zoledronic acid%" OR LOWER(syns_list) LIKE "%zoledronic acid%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1099882', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100047', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100102', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100157', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099992', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099772', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099662', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099607', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100212', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099937', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099827', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099717', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1928 | Q34 | What are the names of the genes that are targeted by the drug Azacitidine in the treatment of Thrombocytopenia? | In the context of Thrombocytopenia, the drug Azacitidine targets the gene DNA methyltransferase 1 and DNA methyltransferase 3 alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thrombocytopenia%" OR LOWER(efo_term) LIKE "%thrombocytopenia%") AND (LOWER(drugName) LIKE "%azacitidine%" OR LOWER(tradeNames_list) LIKE "%azacitidine%" OR LOWER(syns_list) LIKE "%azacitidine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1191976', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191914', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192100', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192038', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.133 | Q34 | What are the names of the genes that are targeted by the drug Afatinib Dimaleate in the treatment of non-small cell lung carcinoma? | In the context of non-small cell lung carcinoma, the drug Afatinib Dimaleate targets the gene epidermal growth factor receptor, erb-b2 receptor tyrosine kinase 2 and erb-b2 receptor tyrosine kinase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%non-small cell lung carcinoma%" OR LOWER(efo_term) LIKE "%non-small cell lung carcinoma%") AND (LOWER(drugName) LIKE "%afatinib dimaleate%" OR LOWER(tradeNames_list) LIKE "%afatinib dimaleate%" OR LOWER(syns_list) LIKE "%afatinib dimaleate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_207186', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207192', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207194', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207196', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207200', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207202', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207204', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207208', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207210', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207212', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207214', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207218', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207220', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207222', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207224', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207226', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207228', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207230', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207232', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207234', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207236', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207240', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207242', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207244', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207246', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207248', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207252', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207254', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207256', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207258', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207260', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207262', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207264', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207266', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207268', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207270', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207272', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207274', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207276', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207278', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207280', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207282', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207284', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207286', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207288', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207290', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207292', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207294', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207296', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207298', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207300', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207304', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207306', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207308', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207310', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207312', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207314', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207318', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207320', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207322', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207324', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207326', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207328', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207330', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207332', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207334', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207336', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207338', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207340', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207342', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207344', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207346', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207348', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207350', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207352', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207354', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207302', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207238', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207206', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207190', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207182', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207178', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207176', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207316', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207250', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207216', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207198', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207188', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207184', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207180', 'drugName': 'Afatinib Dimaleate', 'tradeNames_list': "['Gilotrif']", 'syns_list': "['Afatinib dimaleate', 'Afatinib maleate', 'BIBW-2992 MA2', 'BIBW-2992-MA2BIBW-2992MA2', 'BIBW2992 MA2', 'BIBW2992-MA2']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1584 | Q34 | What are the names of the genes that are targeted by the drug Everolimus in the treatment of tuberous sclerosis? | In the context of tuberous sclerosis, the drug Everolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%tuberous sclerosis%" OR LOWER(efo_term) LIKE "%tuberous sclerosis%") AND (LOWER(drugName) LIKE "%everolimus%" OR LOWER(tradeNames_list) LIKE "%everolimus%" OR LOWER(syns_list) LIKE "%everolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1085102', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085237', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085357', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085370', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085492', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085505', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085507', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085640', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085642', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085762', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085775', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085897', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085910', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085912', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086032', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086045', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086047', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086167', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086180', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086182', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086302', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086317', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086437', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086450', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086452', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086572', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086587', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086707', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086720', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086722', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086842', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086855', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086857', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086977', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086990', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086992', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087112', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087125', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087127', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087247', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087260', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087262', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087382', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087395', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087397', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087517', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087530', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087532', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087652', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087665', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087667', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087800', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087802', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087922', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087935', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087937', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088057', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088072', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088192', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088205', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088207', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088327', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088340', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088342', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088462', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088475', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088477', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088597', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088610', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088612', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088732', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088745', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088747', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088867', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088880', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088882', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089002', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089015', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089017', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089137', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089150', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089152', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089272', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089285', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089287', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089407', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087787', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086315', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085627', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085235', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085087', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084965', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084952', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088070', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086585', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085777', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085372', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085222', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'Adenoma sebaceum', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085100', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084967', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'tuberous sclerosis', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1539 | Q34 | What are the names of the genes that are targeted by the drug Dronabinol in the treatment of cancer? | In the context of cancer, the drug Dronabinol targets the gene cannabinoid receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%dronabinol%" OR LOWER(tradeNames_list) LIKE "%dronabinol%" OR LOWER(syns_list) LIKE "%dronabinol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1073255', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073219', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073327', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073291', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1768 | Q34 | What are the names of the genes that are targeted by the drug Risedronate Sodium in the treatment of Paget disease? | In the context of Paget disease, the drug Risedronate Sodium targets the gene farnesyl diphosphate synthase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%paget disease%" OR LOWER(efo_term) LIKE "%paget disease%") AND (LOWER(drugName) LIKE "%risedronate sodium%" OR LOWER(tradeNames_list) LIKE "%risedronate sodium%" OR LOWER(syns_list) LIKE "%risedronate sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1099463', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'syns_list': "['NE-58095', 'NE-58095 ANHYDROUS', 'NSC-722598', 'NSC-759280Risedronate monosodium', 'Risedronate sodiumRisedronate sodium anhydrous', 'Risedronic acid monosodium salt']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099449', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'syns_list': "['NE-58095', 'NE-58095 ANHYDROUS', 'NSC-722598', 'NSC-759280Risedronate monosodium', 'Risedronate sodiumRisedronate sodium anhydrous', 'Risedronic acid monosodium salt']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099435', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'syns_list': "['NE-58095', 'NE-58095 ANHYDROUS', 'NSC-722598', 'NSC-759280Risedronate monosodium', 'Risedronate sodiumRisedronate sodium anhydrous', 'Risedronic acid monosodium salt']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099428', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'syns_list': "['NE-58095', 'NE-58095 ANHYDROUS', 'NSC-722598', 'NSC-759280Risedronate monosodium', 'Risedronate sodiumRisedronate sodium anhydrous', 'Risedronic acid monosodium salt']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099470', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'syns_list': "['NE-58095', 'NE-58095 ANHYDROUS', 'NSC-722598', 'NSC-759280Risedronate monosodium', 'Risedronate sodiumRisedronate sodium anhydrous', 'Risedronic acid monosodium salt']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099456', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'syns_list': "['NE-58095', 'NE-58095 ANHYDROUS', 'NSC-722598', 'NSC-759280Risedronate monosodium', 'Risedronate sodiumRisedronate sodium anhydrous', 'Risedronic acid monosodium salt']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099442', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'syns_list': "['NE-58095', 'NE-58095 ANHYDROUS', 'NSC-722598', 'NSC-759280Risedronate monosodium', 'Risedronate sodiumRisedronate sodium anhydrous', 'Risedronic acid monosodium salt']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1838 | Q34 | What are the names of the genes that are targeted by the drug Plerixafor in the treatment of childhood cancer? | In the context of childhood cancer, the drug Plerixafor targets the gene C-X-C motif chemokine receptor 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%childhood cancer%" OR LOWER(efo_term) LIKE "%childhood cancer%") AND (LOWER(drugName) LIKE "%plerixafor%" OR LOWER(tradeNames_list) LIKE "%plerixafor%" OR LOWER(syns_list) LIKE "%plerixafor%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1103213', 'drugName': 'Plerixafor', 'tradeNames_list': "['Mozobil']", 'syns_list': "['AMD 3100', 'AMD3100', 'JM 3100', 'Plerixafor', 'Plerixafor hydrochloridePlerixafor octahydrochloride', 'SID 791']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer', 'approvedSymbol': 'CXCR4', 'approvedName': 'C-X-C motif chemokine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1103250', 'drugName': 'Plerixafor', 'tradeNames_list': "['Mozobil']", 'syns_list': "['AMD 3100', 'AMD3100', 'JM 3100', 'Plerixafor', 'Plerixafor hydrochloridePlerixafor octahydrochloride', 'SID 791']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'childhood cancer', 'approvedSymbol': 'CXCR4', 'approvedName': 'C-X-C motif chemokine receptor 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1329 | Q34 | What are the names of the genes that are targeted by the drug Lorlatinib in the treatment of non-small cell lung carcinoma? | In the context of non-small cell lung carcinoma, the drug Lorlatinib targets the gene ALK receptor tyrosine kinase and EMAP like 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%non-small cell lung carcinoma%" OR LOWER(efo_term) LIKE "%non-small cell lung carcinoma%") AND (LOWER(drugName) LIKE "%lorlatinib%" OR LOWER(tradeNames_list) LIKE "%lorlatinib%" OR LOWER(syns_list) LIKE "%lorlatinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_991071', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991095', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991103', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991111', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991127', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991135', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991143', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991159', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991167', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991175', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991183', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991199', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991207', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991215', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991223', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991231', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991239', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991247', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991255', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991263', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991151', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991087', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991055', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991039', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991031', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991191', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991119', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991079', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991063', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991047', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1485 | Q34 | What are the names of the genes that are targeted by the drug Methotrexate in the treatment of immune system disease? | In the context of immune system disease, the drug Methotrexate targets the gene dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%immune system disease%" OR LOWER(efo_term) LIKE "%immune system disease%") AND (LOWER(drugName) LIKE "%methotrexate%" OR LOWER(tradeNames_list) LIKE "%methotrexate%" OR LOWER(syns_list) LIKE "%methotrexate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1057586', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058069', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058230', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058391', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058713', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058874', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059035', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059357', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059518', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059679', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059840', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060162', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060323', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060484', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060645', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060806', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060967', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061128', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061289', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061450', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061611', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061933', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062094', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062255', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062416', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062577', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062899', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063060', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063221', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063382', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063543', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063704', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063865', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064026', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064187', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064348', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064509', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064670', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064831', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064992', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065153', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065314', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065475', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065636', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065797', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065958', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066119', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066280', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066441', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066602', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066763', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067085', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067246', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067407', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067568', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067729', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067890', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068212', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068373', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068534', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068695', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068856', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069017', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069178', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069339', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069500', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069661', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069822', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069983', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070144', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070305', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070466', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070627', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070788', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070949', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071110', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071271', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071432', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071593', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071754', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071915', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072076', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072237', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072398', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066924', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061772', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059196', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057908', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057264', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056942', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056781', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068051', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062738', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060001', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058552', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057747', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057425', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057103', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.166 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of lymphoma? | In the context of lymphoma, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%lymphoma%" OR LOWER(efo_term) LIKE "%lymphoma%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_219504', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218464', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218048', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217840', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219088', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219296', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220128', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220544', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217632', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219712', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218256', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220336', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219920', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218672', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220752', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218880', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218392', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hodgkin Disease', 'efo_term': 'Hodgkins lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218646', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218658', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217771', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218020', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218647', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218028', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hodgkin Disease', 'efo_term': 'classic Hodgkin lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218228', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217619', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia-Lymphoma, Adult T-Cell', 'efo_term': 'adult T-cell leukemia/lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217589', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218807', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217985', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218659', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia-Lymphoma, Adult T-Cell', 'efo_term': 'adult T-cell leukemia/lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217768', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hodgkin Disease', 'efo_term': 'Hodgkins lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217767', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218005', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218652', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hodgkin Disease', 'efo_term': 'classic Hodgkin lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217980', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218395', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217563', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218396', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218604', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217975', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218660', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'T-lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217979', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217607', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218421', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217777', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218018', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218603', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218021', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'lymphoplasmacytic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218022', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218023', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218244', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'T-lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218600', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hodgkin Disease', 'efo_term': 'Hodgkins lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217976', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hodgkin Disease', 'efo_term': 'Hodgkins lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217602', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218034', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217820', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hodgkin Disease', 'efo_term': 'classic Hodgkin lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217564', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217815', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217814', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218452', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'T-lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218231', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217826', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218229', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'lymphoplasmacytic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218226', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217828', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'T-lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217827', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia-Lymphoma, Adult T-Cell', 'efo_term': 'adult T-cell leukemia/lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218642', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218213', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218230', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218193', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217620', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'T-lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218236', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hodgkin Disease', 'efo_term': 'classic Hodgkin lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218242', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218243', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia-Lymphoma, Adult T-Cell', 'efo_term': 'adult T-cell leukemia/lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218450', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217812', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217612', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hodgkin Disease', 'efo_term': 'classic Hodgkin lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218188', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218187', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218434', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218629', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218609', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218599', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218391', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218808', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hodgkin Disease', 'efo_term': 'Hodgkins lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218645', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'lymphoplasmacytic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218401', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218437', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'lymphoplasmacytic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218438', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217810', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218439', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218184', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hodgkin Disease', 'efo_term': 'Hodgkins lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218183', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217797', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217813', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'lymphoplasmacytic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217618', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218436', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217569', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217559', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217604', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217605', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'lymphoplasmacytic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.729 | Q34 | What are the names of the genes that are targeted by the drug Dabrafenib Mesylate in the treatment of thyroid carcinoma? | In the context of thyroid carcinoma, the drug Dabrafenib Mesylate targets the gene B-Raf proto-oncogene, serine/threonine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thyroid carcinoma%" OR LOWER(efo_term) LIKE "%thyroid carcinoma%") AND (LOWER(drugName) LIKE "%dabrafenib mesylate%" OR LOWER(tradeNames_list) LIKE "%dabrafenib mesylate%" OR LOWER(syns_list) LIKE "%dabrafenib mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_752714', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752735', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752742', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752749', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752763', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752770', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752777', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752791', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752798', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752805', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752812', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752826', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752833', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752840', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752847', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752854', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752861', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752868', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752875', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752882', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752889', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752903', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752910', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752917', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752924', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752931', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752945', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752952', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752959', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752966', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752973', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752980', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752896', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752784', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752728', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752700', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752686', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752679', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752938', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752819', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752756', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752721', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752707', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752693', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.292 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of Crohn's disease? | In the context of Crohn's disease, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%crohn's disease%" OR LOWER(efo_term) LIKE "%crohn's disease%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227747', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228602', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228887', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229172', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229742', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230027', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230312', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230882', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231167', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231452', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231737', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232307', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230597', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228317', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227177', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226607', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226322', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232022', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229457', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228032', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227462', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226892', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1320 | Q34 | What are the names of the genes that are targeted by the drug Nitric Oxide in the treatment of pulmonary arterial hypertension? | In the context of pulmonary arterial hypertension, the drug Nitric Oxide targets the gene guanylate cyclase 1 soluble subunit beta 1, guanylate cyclase 1 soluble subunit beta 2 (pseudogene), guanylate cyclase 1 soluble subunit alpha 2 and guanylate cyclase 1 soluble subunit alpha 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pulmonary arterial hypertension%" OR LOWER(efo_term) LIKE "%pulmonary arterial hypertension%") AND (LOWER(drugName) LIKE "%nitric oxide%" OR LOWER(tradeNames_list) LIKE "%nitric oxide%" OR LOWER(syns_list) LIKE "%nitric oxide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_974423', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974585', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974639', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974693', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974801', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974855', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974909', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975017', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975071', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975125', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975179', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975287', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975341', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975395', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975449', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975503', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975557', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975611', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975665', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975719', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975773', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975881', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975935', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975989', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976043', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976097', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976205', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976259', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976313', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976367', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976421', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976475', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976529', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976583', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976637', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976691', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976745', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976799', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976853', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976907', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976961', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977015', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977069', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977123', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977177', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977231', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977285', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977339', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977393', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977447', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977501', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977609', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977663', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977717', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977771', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977825', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977879', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977987', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_978041', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978095', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978149', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978203', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978257', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978311', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978365', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978419', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978473', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978527', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978581', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978635', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978689', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978743', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978797', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978851', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978905', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978959', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979013', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979067', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979121', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979175', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979229', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979283', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979337', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979391', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979445', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979499', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_977555', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975827', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974963', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974531', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974315', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974207', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974153', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977933', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976151', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975233', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974747', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974477', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974369', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974261', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1922 | Q34 | What are the names of the genes that are targeted by the drug Bempedoic Acid in the treatment of atherosclerosis? | In the context of atherosclerosis, the drug Bempedoic Acid targets the gene ATP citrate lyase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%atherosclerosis%" OR LOWER(efo_term) LIKE "%atherosclerosis%") AND (LOWER(drugName) LIKE "%bempedoic acid%" OR LOWER(tradeNames_list) LIKE "%bempedoic acid%" OR LOWER(syns_list) LIKE "%bempedoic acid%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1191842', 'drugName': 'Bempedoic Acid', 'tradeNames_list': "['Nexletol']", 'syns_list': "['Bempedoic acid', 'ESP-55016', 'ETC-1002', 'ETC1002']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'ACLY', 'approvedName': 'ATP citrate lyase'}, {'UUID': 'DrugTargetsIndication121923_text_1191810', 'drugName': 'Bempedoic Acid', 'tradeNames_list': "['Nexletol']", 'syns_list': "['Bempedoic acid', 'ESP-55016', 'ETC-1002', 'ETC1002']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'ACLY', 'approvedName': 'ATP citrate lyase'}, {'UUID': 'DrugTargetsIndication121923_text_1191802', 'drugName': 'Bempedoic Acid', 'tradeNames_list': "['Nexletol']", 'syns_list': "['Bempedoic acid', 'ESP-55016', 'ETC-1002', 'ETC1002']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'ACLY', 'approvedName': 'ATP citrate lyase'}, {'UUID': 'DrugTargetsIndication121923_text_1191826', 'drugName': 'Bempedoic Acid', 'tradeNames_list': "['Nexletol']", 'syns_list': "['Bempedoic acid', 'ESP-55016', 'ETC-1002', 'ETC1002']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'ACLY', 'approvedName': 'ATP citrate lyase'}, {'UUID': 'DrugTargetsIndication121923_text_1191834', 'drugName': 'Bempedoic Acid', 'tradeNames_list': "['Nexletol']", 'syns_list': "['Bempedoic acid', 'ESP-55016', 'ETC-1002', 'ETC1002']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'ACLY', 'approvedName': 'ATP citrate lyase'}, {'UUID': 'DrugTargetsIndication121923_text_1191818', 'drugName': 'Bempedoic Acid', 'tradeNames_list': "['Nexletol']", 'syns_list': "['Bempedoic acid', 'ESP-55016', 'ETC-1002', 'ETC1002']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atherosclerosis', 'efo_term': 'atherosclerosis', 'approvedSymbol': 'ACLY', 'approvedName': 'ATP citrate lyase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1878 | Q34 | What are the names of the genes that are targeted by the drug Ivabradine in the treatment of cardiovascular disease? | In the context of cardiovascular disease, the drug Ivabradine targets the gene hyperpolarization activated cyclic nucleotide gated potassium channel 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiovascular disease%" OR LOWER(efo_term) LIKE "%cardiovascular disease%") AND (LOWER(drugName) LIKE "%ivabradine%" OR LOWER(tradeNames_list) LIKE "%ivabradine%" OR LOWER(syns_list) LIKE "%ivabradine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1148502', 'drugName': 'Ivabradine', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['Ivabradine', 'S-16257']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148559', 'drugName': 'Ivabradine', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['Ivabradine', 'S-16257']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148578', 'drugName': 'Ivabradine', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['Ivabradine', 'S-16257']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148597', 'drugName': 'Ivabradine', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['Ivabradine', 'S-16257']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148635', 'drugName': 'Ivabradine', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['Ivabradine', 'S-16257']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148654', 'drugName': 'Ivabradine', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['Ivabradine', 'S-16257']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148673', 'drugName': 'Ivabradine', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['Ivabradine', 'S-16257']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148711', 'drugName': 'Ivabradine', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['Ivabradine', 'S-16257']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148730', 'drugName': 'Ivabradine', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['Ivabradine', 'S-16257']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148749', 'drugName': 'Ivabradine', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['Ivabradine', 'S-16257']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148768', 'drugName': 'Ivabradine', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['Ivabradine', 'S-16257']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148540', 'drugName': 'Ivabradine', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['Ivabradine', 'S-16257']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148464', 'drugName': 'Ivabradine', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['Ivabradine', 'S-16257']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148426', 'drugName': 'Ivabradine', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['Ivabradine', 'S-16257']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148407', 'drugName': 'Ivabradine', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['Ivabradine', 'S-16257']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148692', 'drugName': 'Ivabradine', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['Ivabradine', 'S-16257']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148616', 'drugName': 'Ivabradine', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['Ivabradine', 'S-16257']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148521', 'drugName': 'Ivabradine', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['Ivabradine', 'S-16257']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148483', 'drugName': 'Ivabradine', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['Ivabradine', 'S-16257']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148445', 'drugName': 'Ivabradine', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['Ivabradine', 'S-16257']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.983 | Q34 | What are the names of the genes that are targeted by the drug Abemaciclib in the treatment of breast neoplasm? | In the context of breast neoplasm, the drug Abemaciclib targets the gene cyclin dependent kinase 4 and cyclin dependent kinase 6. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast neoplasm%" OR LOWER(efo_term) LIKE "%breast neoplasm%") AND (LOWER(drugName) LIKE "%abemaciclib%" OR LOWER(tradeNames_list) LIKE "%abemaciclib%" OR LOWER(syns_list) LIKE "%abemaciclib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_850521', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849246', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850269', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849504', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849195', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850626', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849658', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849402', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850167', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849450', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850317', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849960', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849297', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850525', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849093', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850572', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849606', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850627', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849351', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850674', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849199', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849399', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849756', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849096', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850168', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849147', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849453', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850371', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849250', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849912', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849501', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850372', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849097', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850419', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850014', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850623', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849555', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849556', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849301', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850576', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849603', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850575', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849607', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850725', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849198', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849654', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849657', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850678', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849352', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850677', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849705', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849709', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850113', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850066', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850117', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849759', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849760', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850219', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849807', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849810', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849811', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850218', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849249', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849858', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849861', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850473', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849454', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850270', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849909', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850368', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849913', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850321', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850320', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850470', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849963', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849964', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849505', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850423', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850011', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850422', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850015', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850728', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849300', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850062', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850065', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850776', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850729', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850474', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850266', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850164', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850116', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849708', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849144', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849403', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850215', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849148', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850524', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849348', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849862', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849552', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1346 | Q34 | What are the names of the genes that are targeted by the drug Capsaicin in the treatment of frozen shoulder? | In the context of frozen shoulder, the drug Capsaicin targets the gene transient receptor potential cation channel subfamily V member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%frozen shoulder%" OR LOWER(efo_term) LIKE "%frozen shoulder%") AND (LOWER(drugName) LIKE "%capsaicin%" OR LOWER(tradeNames_list) LIKE "%capsaicin%" OR LOWER(syns_list) LIKE "%capsaicin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_993230', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993156', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993082', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993045', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993267', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993193', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993119', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.784 | Q34 | What are the names of the genes that are targeted by the drug Talazoparib Tosylate in the treatment of breast neoplasm? | In the context of breast neoplasm, the drug Talazoparib Tosylate targets the gene poly(ADP-ribose) polymerase 2 and poly(ADP-ribose) polymerase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast neoplasm%" OR LOWER(efo_term) LIKE "%breast neoplasm%") AND (LOWER(drugName) LIKE "%talazoparib tosylate%" OR LOWER(tradeNames_list) LIKE "%talazoparib tosylate%" OR LOWER(syns_list) LIKE "%talazoparib tosylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_794879', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794718', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794851', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794731', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794723', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794809', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794738', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794725', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794837', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794745', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794906', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794865', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794752', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794927', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794732', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794802', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794759', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794934', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794737', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794816', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794766', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794739', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794830', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794773', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794898', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794744', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794780', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794912', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794746', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794858', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794787', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794913', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794751', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794872', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794794', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794933', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794753', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794800', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794801', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794928', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794758', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794807', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794808', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794940', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794760', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794814', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794815', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794935', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794765', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794821', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794822', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794767', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794828', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794829', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794892', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794772', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794835', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794900', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794774', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794842', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794843', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794899', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794779', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794849', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794850', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794920', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794781', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794856', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794857', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794907', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794786', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794863', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794864', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794919', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794788', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794870', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794871', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794914', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794793', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794877', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794878', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794941', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794795', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794884', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794885', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794947', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794942', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794921', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794905', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794893', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794891', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794886', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794823', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794836', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794844', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794730', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794926', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_794724', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794716', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_794717', 'drugName': 'Talazoparib Tosylate', 'tradeNames_list': "['Talzenna']", 'syns_list': "['BMN 673ts', 'BMN-673TS', 'Talazoparib tosilate', 'Talazoparib tosylate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.845 | Q34 | What are the names of the genes that are targeted by the drug Celecoxib in the treatment of juvenile idiopathic arthritis? | In the context of juvenile idiopathic arthritis, the drug Celecoxib targets the gene prostaglandin-endoperoxide synthase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%juvenile idiopathic arthritis%" OR LOWER(efo_term) LIKE "%juvenile idiopathic arthritis%") AND (LOWER(drugName) LIKE "%celecoxib%" OR LOWER(tradeNames_list) LIKE "%celecoxib%" OR LOWER(syns_list) LIKE "%celecoxib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_833496', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833052', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832941', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833274', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833385', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833163', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.350 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of cystoid macular edema? | In the context of cystoid macular edema, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cystoid macular edema%" OR LOWER(efo_term) LIKE "%cystoid macular edema%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227806', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228661', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228946', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229231', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229801', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230086', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230371', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230941', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231226', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231511', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231796', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232366', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230656', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228376', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227236', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226666', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226381', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232081', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229516', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228091', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227521', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226951', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'cystoid macular edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1925 | Q34 | What are the names of the genes that are targeted by the drug Avacopan in the treatment of Granulomatosis with Polyangiitis? | In the context of Granulomatosis with Polyangiitis, the drug Avacopan targets the gene complement C5a receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%granulomatosis with polyangiitis%" OR LOWER(efo_term) LIKE "%granulomatosis with polyangiitis%") AND (LOWER(drugName) LIKE "%avacopan%" OR LOWER(tradeNames_list) LIKE "%avacopan%" OR LOWER(syns_list) LIKE "%avacopan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1191849', 'drugName': 'Avacopan', 'tradeNames_list': "['Tavneos']", 'syns_list': "['Avacopan', 'CCX-168', 'CCX168', 'Ccx168']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Granulomatosis with Polyangiitis', 'efo_term': 'Granulomatosis with Polyangiitis', 'approvedSymbol': 'C5AR1', 'approvedName': 'complement C5a receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191857', 'drugName': 'Avacopan', 'tradeNames_list': "['Tavneos']", 'syns_list': "['Avacopan', 'CCX-168', 'CCX168', 'Ccx168']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Granulomatosis with Polyangiitis', 'efo_term': 'Granulomatosis with Polyangiitis', 'approvedSymbol': 'C5AR1', 'approvedName': 'complement C5a receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.575 | Q34 | What are the names of the genes that are targeted by the drug Lidocaine in the treatment of burn? | In the context of burn, the drug Lidocaine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%burn%" OR LOWER(efo_term) LIKE "%burn%") AND (LOWER(drugName) LIKE "%lidocaine%" OR LOWER(tradeNames_list) LIKE "%lidocaine%" OR LOWER(syns_list) LIKE "%lidocaine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_638020', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638244', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638250', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638359', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638474', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638480', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638589', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638704', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638710', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638819', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638825', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638940', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639049', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639055', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639164', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639170', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639279', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639285', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639394', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639400', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639509', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639624', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639630', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639739', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639745', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639854', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639969', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639975', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640084', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640090', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640199', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640205', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640314', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640320', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640429', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640435', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640544', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640550', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640659', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640665', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640774', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640780', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640889', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640895', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641004', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641010', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641119', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641125', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641234', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641240', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641349', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641464', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641470', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641579', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641585', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641694', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641700', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641815', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641924', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_641930', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642039', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642045', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642154', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642160', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642269', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642275', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642384', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642390', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642499', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642505', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642614', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642620', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642729', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642735', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642844', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642850', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642959', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642965', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643074', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643080', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643189', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643195', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643304', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643310', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643419', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643425', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_641355', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639515', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638595', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638135', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637905', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637790', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637784', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_641809', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639860', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_638934', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638365', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638129', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638014', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637899', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1313 | Q34 | What are the names of the genes that are targeted by the drug Vericiguat in the treatment of heart failure? | In the context of heart failure, the drug Vericiguat targets the gene guanylate cyclase 1 soluble subunit beta 1, guanylate cyclase 1 soluble subunit beta 2 (pseudogene), guanylate cyclase 1 soluble subunit alpha 2 and guanylate cyclase 1 soluble subunit alpha 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%heart failure%" OR LOWER(efo_term) LIKE "%heart failure%") AND (LOWER(drugName) LIKE "%vericiguat%" OR LOWER(tradeNames_list) LIKE "%vericiguat%" OR LOWER(syns_list) LIKE "%vericiguat%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_972741', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972750', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972753', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972756', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972762', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972765', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972768', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972774', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972777', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972780', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972783', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972789', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972792', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972795', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972798', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972801', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972804', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972807', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972810', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972813', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972816', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972822', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972825', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972828', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972831', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972834', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972840', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972843', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972846', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972849', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972852', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972855', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972858', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972861', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972864', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972867', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972870', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972873', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972876', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972879', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972882', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972885', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972888', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972891', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972894', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972897', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972900', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972903', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972819', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972771', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972747', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972735', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972729', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972726', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972837', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972786', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972759', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972744', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972738', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972732', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1869 | Q34 | What are the names of the genes that are targeted by the drug Lenalidomide in the treatment of immune system disease? | In the context of immune system disease, the drug Lenalidomide targets the gene cereblon, damage specific DNA binding protein 1, cullin 4A and ring-box 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%immune system disease%" OR LOWER(efo_term) LIKE "%immune system disease%") AND (LOWER(drugName) LIKE "%lenalidomide%" OR LOWER(tradeNames_list) LIKE "%lenalidomide%" OR LOWER(syns_list) LIKE "%lenalidomide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1106170', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106431', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106518', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106605', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106779', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106866', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106953', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107127', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107214', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107301', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107388', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107562', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107649', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107736', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107823', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107910', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107997', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108084', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108171', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108258', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108345', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108519', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108606', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108693', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108780', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108867', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109041', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109128', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109215', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109302', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109389', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109476', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109563', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109650', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109737', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109824', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109911', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109998', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110085', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110172', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110259', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110346', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110433', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110520', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110607', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110694', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110781', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110868', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110955', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111042', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111129', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111303', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111390', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111477', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111564', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111651', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111738', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111912', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111999', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112086', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112173', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112260', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112347', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112434', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112521', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112608', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112695', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112782', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112869', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112956', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113043', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113130', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113217', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113304', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113391', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113478', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113565', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113652', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113739', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113826', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113913', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1114000', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1114087', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1114174', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1114261', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1114348', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111216', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108432', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107040', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106344', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1105996', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1105822', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1105735', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111825', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108954', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107475', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106692', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106257', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106083', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1105909', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1455 | Q34 | What are the names of the genes that are targeted by the drug Lifitegrast in the treatment of dry eye syndrome? | In the context of dry eye syndrome, the drug Lifitegrast targets the gene integrin subunit alpha L and integrin subunit beta 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%dry eye syndrome%" OR LOWER(efo_term) LIKE "%dry eye syndrome%") AND (LOWER(drugName) LIKE "%lifitegrast%" OR LOWER(tradeNames_list) LIKE "%lifitegrast%" OR LOWER(syns_list) LIKE "%lifitegrast%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1053376', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053388', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053392', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053396', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053404', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053408', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053412', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053420', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053424', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053428', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053432', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053440', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053444', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053448', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053452', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053456', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053460', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053464', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053468', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053472', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053476', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053480', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053416', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053384', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053368', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053360', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053356', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053436', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053400', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053380', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053372', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053364', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dry Eye Syndromes', 'efo_term': 'dry eye syndrome', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1577 | Q34 | What are the names of the genes that are targeted by the drug Everolimus in the treatment of anaplastic astrocytoma? | In the context of anaplastic astrocytoma, the drug Everolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%anaplastic astrocytoma%" OR LOWER(efo_term) LIKE "%anaplastic astrocytoma%") AND (LOWER(drugName) LIKE "%everolimus%" OR LOWER(tradeNames_list) LIKE "%everolimus%" OR LOWER(syns_list) LIKE "%everolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1085635', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086040', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086175', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086310', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086580', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086715', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086850', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087120', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087255', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087390', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087525', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087795', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087930', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088065', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088200', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088335', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088470', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088605', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088740', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088875', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089010', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089280', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089415', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089550', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089685', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089820', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090090', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090225', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090360', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090495', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090630', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089145', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086985', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085905', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085365', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085095', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084960', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089955', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087660', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086445', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085770', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085500', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085230', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1390 | Q34 | What are the names of the genes that are targeted by the drug Brimonidine Tartrate in the treatment of rosacea? | In the context of rosacea, the drug Brimonidine Tartrate targets the gene adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rosacea%" OR LOWER(efo_term) LIKE "%rosacea%") AND (LOWER(drugName) LIKE "%brimonidine tartrate%" OR LOWER(tradeNames_list) LIKE "%brimonidine tartrate%" OR LOWER(syns_list) LIKE "%brimonidine tartrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1034129', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034174', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034189', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034204', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034234', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034249', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034264', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034294', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034309', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034324', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034339', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034369', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034384', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034399', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034414', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034429', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034444', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034459', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034474', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034489', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034504', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034534', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034549', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034564', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034579', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034594', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034624', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034639', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034654', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034669', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034684', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034699', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034714', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034729', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034744', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034759', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034774', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034789', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034804', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034819', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034834', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034849', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034864', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034879', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034894', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034909', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034924', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034939', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034954', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034969', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034984', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035014', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035029', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035044', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035059', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035074', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035089', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035119', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035134', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035149', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035164', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035179', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035194', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035209', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035224', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035239', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035254', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035269', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035284', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035299', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034999', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034519', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034279', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034159', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034099', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034069', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034054', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1035104', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034609', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034354', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034219', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034144', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034114', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034084', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.989 | Q34 | What are the names of the genes that are targeted by the drug Palbociclib in the treatment of breast neoplasm? | In the context of breast neoplasm, the drug Palbociclib targets the gene cyclin dependent kinase 4, cyclin dependent kinase 6 and cyclin D1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast neoplasm%" OR LOWER(efo_term) LIKE "%breast neoplasm%") AND (LOWER(drugName) LIKE "%palbociclib%" OR LOWER(tradeNames_list) LIKE "%palbociclib%" OR LOWER(syns_list) LIKE "%palbociclib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_851403', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851447', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851487', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851490', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851531', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851534', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851535', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851578', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851579', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851619', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851622', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851663', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851666', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851667', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851707', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851710', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851711', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851751', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851754', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851755', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851795', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851799', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851839', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851842', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851843', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851883', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851887', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851927', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851930', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851931', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851971', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851974', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851975', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852015', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852018', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852019', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852059', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852062', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852063', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852103', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852106', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852107', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852147', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852150', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852151', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852191', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852194', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852195', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852235', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852238', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852239', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852282', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852283', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852323', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852326', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852327', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852367', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852371', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852411', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852414', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852415', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852455', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852458', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852459', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852499', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852502', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852503', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852543', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852546', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852547', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852587', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852590', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852591', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852631', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852634', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852635', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852675', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852678', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852679', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852719', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852722', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852723', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852763', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852766', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852767', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852807', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_852279', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851798', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851575', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851446', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851399', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851358', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851355', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852370', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851886', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851623', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851491', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851443', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851402', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851359', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.462 | Q34 | What are the names of the genes that are targeted by the drug Phenylephrine Hydrochloride in the treatment of hemorrhoid? | In the context of hemorrhoid, the drug Phenylephrine Hydrochloride targets the gene adrenoceptor alpha 1A, adrenoceptor alpha 1D and adrenoceptor alpha 1B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hemorrhoid%" OR LOWER(efo_term) LIKE "%hemorrhoid%") AND (LOWER(drugName) LIKE "%phenylephrine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%phenylephrine hydrochloride%" OR LOWER(syns_list) LIKE "%phenylephrine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_416704', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_416632', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416614', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416668', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_416686', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_416650', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.377 | Q34 | What are the names of the genes that are targeted by the drug Hydrocortisone in the treatment of hemorrhoid? | In the context of hemorrhoid, the drug Hydrocortisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hemorrhoid%" OR LOWER(efo_term) LIKE "%hemorrhoid%") AND (LOWER(drugName) LIKE "%hydrocortisone%" OR LOWER(tradeNames_list) LIKE "%hydrocortisone%" OR LOWER(syns_list) LIKE "%hydrocortisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_241226', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241472', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241554', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241636', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241800', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241882', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241390', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241062', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240898', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240816', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241718', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241308', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241144', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240980', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1327 | Q34 | What are the names of the genes that are targeted by the drug Lorlatinib in the treatment of lymphoma? | In the context of lymphoma, the drug Lorlatinib targets the gene ALK receptor tyrosine kinase and EMAP like 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%lymphoma%" OR LOWER(efo_term) LIKE "%lymphoma%") AND (LOWER(drugName) LIKE "%lorlatinib%" OR LOWER(tradeNames_list) LIKE "%lorlatinib%" OR LOWER(syns_list) LIKE "%lorlatinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_991125', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991165', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991045', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991061', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991205', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991213', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991101', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991229', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991141', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991181', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991197', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991221', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991173', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991117', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991157', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991029', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991093', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991085', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991109', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991077', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991237', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991253', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991037', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991133', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991149', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991069', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991053', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991261', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991189', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991245', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991027', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991059', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991091', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991155', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991099', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991171', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991179', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991067', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991107', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991187', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991195', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991115', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991203', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991211', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991035', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991075', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991123', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991219', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991227', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991163', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991131', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991235', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991243', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991051', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991043', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991139', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991251', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991259', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991083', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991147', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Large-Cell, Anaplastic', 'efo_term': 'anaplastic large cell lymphoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.335 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of iritis? | In the context of iritis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%iritis%" OR LOWER(efo_term) LIKE "%iritis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227791', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228646', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228931', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229216', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229786', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230071', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230356', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230926', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231211', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231496', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231781', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232351', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230641', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228361', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227221', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226651', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226366', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232066', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229501', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228076', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227506', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226936', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iritis', 'efo_term': 'iritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1554 | Q34 | What are the names of the genes that are targeted by the drug Vorinostat in the treatment of Cutaneous T-cell lymphoma? | In the context of Cutaneous T-cell lymphoma, the drug Vorinostat targets the gene histone deacetylase 1, histone deacetylase 3, histone deacetylase 6 and histone deacetylase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cutaneous t-cell lymphoma%" OR LOWER(efo_term) LIKE "%cutaneous t-cell lymphoma%") AND (LOWER(drugName) LIKE "%vorinostat%" OR LOWER(tradeNames_list) LIKE "%vorinostat%" OR LOWER(syns_list) LIKE "%vorinostat%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1077139', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077403', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077491', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077579', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077755', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077843', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077931', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078107', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078195', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078283', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078371', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078547', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078635', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078723', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078811', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078899', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078987', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1079075', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079163', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079251', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079339', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079515', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079603', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079691', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079779', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079427', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1077315', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076963', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076787', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076699', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1078019', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078459', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1077667', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077227', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077051', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076875', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Cutaneous', 'efo_term': 'Cutaneous T-cell lymphoma', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1744 | Q34 | What are the names of the genes that are targeted by the drug Esomeprazole Magnesium in the treatment of rheumatoid arthritis? | In the context of rheumatoid arthritis, the drug Esomeprazole Magnesium targets the gene ATPase H+/K+ transporting subunit alpha and ATPase H+/K+ transporting subunit beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatoid arthritis%" OR LOWER(efo_term) LIKE "%rheumatoid arthritis%") AND (LOWER(drugName) LIKE "%esomeprazole magnesium%" OR LOWER(tradeNames_list) LIKE "%esomeprazole magnesium%" OR LOWER(syns_list) LIKE "%esomeprazole magnesium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097871', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097859', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097895', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097883', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1443 | Q34 | What are the names of the genes that are targeted by the drug Amlodipine Benzoate in the treatment of heart failure? | In the context of heart failure, the drug Amlodipine Benzoate targets the gene calcium voltage-gated channel subunit alpha1 C, calcium voltage-gated channel subunit alpha1 S, calcium voltage-gated channel subunit alpha1 D and calcium voltage-gated channel subunit alpha1 F. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%heart failure%" OR LOWER(efo_term) LIKE "%heart failure%") AND (LOWER(drugName) LIKE "%amlodipine benzoate%" OR LOWER(tradeNames_list) LIKE "%amlodipine benzoate%" OR LOWER(syns_list) LIKE "%amlodipine benzoate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1044030', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044048', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044054', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044060', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044072', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044078', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044084', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044096', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044102', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044108', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044114', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044126', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044132', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044138', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044144', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044150', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044156', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044162', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044168', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044174', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044180', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044186', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044090', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044042', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044018', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044006', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044000', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044120', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044066', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044036', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044024', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044012', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.822 | Q34 | What are the names of the genes that are targeted by the drug Nepafenac in the treatment of inflammation? | In the context of inflammation, the drug Nepafenac targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%inflammation%" OR LOWER(efo_term) LIKE "%inflammation%") AND (LOWER(drugName) LIKE "%nepafenac%" OR LOWER(tradeNames_list) LIKE "%nepafenac%" OR LOWER(syns_list) LIKE "%nepafenac%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828596', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828605', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828606', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828610', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828615', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828616', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828620', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828625', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828626', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828630', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828631', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828636', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828640', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828641', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828621', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828601', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828591', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828586', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828585', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828635', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828611', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828600', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828595', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828590', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1501 | Q34 | What are the names of the genes that are targeted by the drug Methotrexate in the treatment of lung cancer? | In the context of lung cancer, the drug Methotrexate targets the gene dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%lung cancer%" OR LOWER(efo_term) LIKE "%lung cancer%") AND (LOWER(drugName) LIKE "%methotrexate%" OR LOWER(tradeNames_list) LIKE "%methotrexate%" OR LOWER(syns_list) LIKE "%methotrexate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1057602', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058085', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058246', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058407', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058729', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058890', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059051', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059373', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059534', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059695', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059856', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060178', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060339', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060500', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060661', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060822', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060983', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061144', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061305', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061466', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061627', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061949', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062110', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062271', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062432', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062593', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062915', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063076', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063237', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063398', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063559', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063720', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063881', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064042', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064203', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064364', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064525', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064686', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064847', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065008', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065169', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065330', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065491', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065652', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065813', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065974', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066135', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066296', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066457', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066618', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066779', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067101', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067262', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067423', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067584', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067745', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067906', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068228', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068389', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068550', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068711', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068872', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069033', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069194', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069355', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069516', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069677', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069838', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069999', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070160', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070321', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070482', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070643', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070804', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070965', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071126', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071287', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071448', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071609', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071770', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071931', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072092', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072253', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072414', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066940', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061788', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059212', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057924', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057280', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056958', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056797', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068067', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062754', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060017', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058568', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057763', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057441', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057119', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.969 | Q34 | What are the names of the genes that are targeted by the drug Upadacitinib in the treatment of immune system disease? | In the context of immune system disease, the drug Upadacitinib targets the gene Janus kinase 1, Janus kinase 3, tyrosine kinase 2 and Janus kinase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%immune system disease%" OR LOWER(efo_term) LIKE "%immune system disease%") AND (LOWER(drugName) LIKE "%upadacitinib%" OR LOWER(tradeNames_list) LIKE "%upadacitinib%" OR LOWER(syns_list) LIKE "%upadacitinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_846832', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846868', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846880', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846892', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846916', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846928', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846940', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846964', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846976', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846988', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847000', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847024', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847036', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847048', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847060', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847072', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847084', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847096', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847108', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847120', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847132', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847156', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847168', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847180', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847192', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847204', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847228', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847240', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847252', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847264', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847276', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847288', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847300', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847312', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847324', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847336', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847348', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847360', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847372', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847384', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847396', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847408', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847420', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847432', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847444', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847456', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847468', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847480', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847492', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847504', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847516', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847540', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847552', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847564', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847576', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847588', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847600', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847624', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847636', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847648', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847660', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847672', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847684', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847696', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847708', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847720', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847732', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847744', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847756', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847768', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847780', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847792', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847804', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847816', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847828', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847840', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847852', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847864', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847876', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847888', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847900', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847912', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847924', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847936', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847948', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847960', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847528', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847144', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846952', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846856', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846808', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846784', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846772', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847612', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847216', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847012', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846904', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846844', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846820', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846796', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1840 | Q34 | What are the names of the genes that are targeted by the drug Crofelemer in the treatment of AIDS? | In the context of AIDS, the drug Crofelemer targets the gene CF transmembrane conductance regulator and anoctamin 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%aids%" OR LOWER(efo_term) LIKE "%aids%") AND (LOWER(drugName) LIKE "%crofelemer%" OR LOWER(tradeNames_list) LIKE "%crofelemer%" OR LOWER(syns_list) LIKE "%crofelemer%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1103275', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'syns_list': "['Crofelemer', 'NP-303', 'SP-303', 'TRN-002']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS', 'approvedSymbol': 'ANO1', 'approvedName': 'anoctamin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1103259', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'syns_list': "['Crofelemer', 'NP-303', 'SP-303', 'TRN-002']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103255', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'syns_list': "['Crofelemer', 'NP-303', 'SP-303', 'TRN-002']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103267', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'syns_list': "['Crofelemer', 'NP-303', 'SP-303', 'TRN-002']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS', 'approvedSymbol': 'ANO1', 'approvedName': 'anoctamin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1103271', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'syns_list': "['Crofelemer', 'NP-303', 'SP-303', 'TRN-002']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS', 'approvedSymbol': 'ANO1', 'approvedName': 'anoctamin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1103263', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'syns_list': "['Crofelemer', 'NP-303', 'SP-303', 'TRN-002']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1741 | Q34 | What are the names of the genes that are targeted by the drug Pantoprazole Sodium in the treatment of gastroesophageal reflux disease? | In the context of gastroesophageal reflux disease, the drug Pantoprazole Sodium targets the gene ATPase H+/K+ transporting subunit alpha and ATPase H+/K+ transporting subunit beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%gastroesophageal reflux disease%" OR LOWER(efo_term) LIKE "%gastroesophageal reflux disease%") AND (LOWER(drugName) LIKE "%pantoprazole sodium%" OR LOWER(tradeNames_list) LIKE "%pantoprazole sodium%" OR LOWER(syns_list) LIKE "%pantoprazole sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097772', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097787', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097792', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097797', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097807', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097812', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097817', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097827', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097832', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097837', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097842', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097852', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097822', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097782', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097762', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097752', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097747', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097847', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097802', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097777', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097767', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097757', 'drugName': 'Pantoprazole Sodium', 'tradeNames_list': "['Pantoprazole sodium', 'Protonix', 'Protonix iv']", 'syns_list': "['Controloc control', 'Pantoprazole (as sodium)', 'Pantoprazole sodiumPantoprazole sodium hydrate', 'Pantoprazole sodium sesquihydratePantozol control', 'Somac control']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1910 | Q34 | What are the names of the genes that are targeted by the drug Travoprost in the treatment of ocular hypertension? | In the context of ocular hypertension, the drug Travoprost targets the gene prostaglandin F receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ocular hypertension%" OR LOWER(efo_term) LIKE "%ocular hypertension%") AND (LOWER(drugName) LIKE "%travoprost%" OR LOWER(tradeNames_list) LIKE "%travoprost%" OR LOWER(syns_list) LIKE "%travoprost%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149428', 'drugName': 'Travoprost', 'tradeNames_list': "['Izba', 'Travatan', 'Travatan z', 'Travoprost']", 'syns_list': "['AL-6221', 'NSC-760366', 'Otx-tp', 'Travoprost']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149420', 'drugName': 'Travoprost', 'tradeNames_list': "['Izba', 'Travatan', 'Travatan z', 'Travoprost']", 'syns_list': "['AL-6221', 'NSC-760366', 'Otx-tp', 'Travoprost']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149412', 'drugName': 'Travoprost', 'tradeNames_list': "['Izba', 'Travatan', 'Travatan z', 'Travoprost']", 'syns_list': "['AL-6221', 'NSC-760366', 'Otx-tp', 'Travoprost']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149408', 'drugName': 'Travoprost', 'tradeNames_list': "['Izba', 'Travatan', 'Travatan z', 'Travoprost']", 'syns_list': "['AL-6221', 'NSC-760366', 'Otx-tp', 'Travoprost']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149432', 'drugName': 'Travoprost', 'tradeNames_list': "['Izba', 'Travatan', 'Travatan z', 'Travoprost']", 'syns_list': "['AL-6221', 'NSC-760366', 'Otx-tp', 'Travoprost']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149424', 'drugName': 'Travoprost', 'tradeNames_list': "['Izba', 'Travatan', 'Travatan z', 'Travoprost']", 'syns_list': "['AL-6221', 'NSC-760366', 'Otx-tp', 'Travoprost']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149416', 'drugName': 'Travoprost', 'tradeNames_list': "['Izba', 'Travatan', 'Travatan z', 'Travoprost']", 'syns_list': "['AL-6221', 'NSC-760366', 'Otx-tp', 'Travoprost']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1114 | Q34 | What are the names of the genes that are targeted by the drug Ivosidenib in the treatment of acute myeloid leukemia? | In the context of acute myeloid leukemia, the drug Ivosidenib targets the gene isocitrate dehydrogenase (NADP(+)) 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%acute myeloid leukemia%" OR LOWER(efo_term) LIKE "%acute myeloid leukemia%") AND (LOWER(drugName) LIKE "%ivosidenib%" OR LOWER(tradeNames_list) LIKE "%ivosidenib%" OR LOWER(syns_list) LIKE "%ivosidenib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_924604', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924631', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924640', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924649', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924667', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924676', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924685', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924703', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924712', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924721', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924730', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924748', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924757', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924766', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924775', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924784', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924793', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924694', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924622', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924586', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924568', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924559', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924739', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924658', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924613', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924595', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'UUID': 'DrugTargetsIndication121923_text_924577', 'drugName': 'Ivosidenib', 'tradeNames_list': "['Tibsovo']", 'syns_list': "['AG-120', 'Ivosidenib']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH1', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.330 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of erythema multiforme? | In the context of erythema multiforme, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%erythema multiforme%" OR LOWER(efo_term) LIKE "%erythema multiforme%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227786', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228641', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228926', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229211', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229781', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230066', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230351', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230921', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231206', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231491', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231776', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232346', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230636', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228356', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227216', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226646', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226361', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232061', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229496', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228071', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227501', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226931', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1631 | Q34 | What are the names of the genes that are targeted by the drug Dabigatran in the treatment of Thromboembolism? | Dabigatran has not been approved by the FDA as a treatment for Thromboembolism, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target name is coagulation factor II, thrombin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thromboembolism%" OR LOWER(efo_term) LIKE "%thromboembolism%") AND (LOWER(drugName) LIKE "%dabigatran%" OR LOWER(tradeNames_list) LIKE "%dabigatran%" OR LOWER(syns_list) LIKE "%dabigatran%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1092687', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092709', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092713', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092722', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092735', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092739', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092748', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092761', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092765', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092774', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092778', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092791', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092800', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092804', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092813', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092817', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092826', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092830', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092839', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092843', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092852', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092865', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092869', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092878', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092882', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092891', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092904', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092908', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092917', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092921', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092930', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092934', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092943', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092947', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092956', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092960', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092969', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092973', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092982', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092986', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092995', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092999', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093008', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093012', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093021', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093025', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093034', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093038', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093047', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093051', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093060', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093073', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093077', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093086', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093090', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093099', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093103', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093116', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093125', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093129', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093138', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093142', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093151', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093155', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093164', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093168', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093177', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093181', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093190', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093194', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093203', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093207', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093216', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093220', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093229', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093233', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093242', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093246', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093255', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093259', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093268', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093272', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093281', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093285', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093294', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093298', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093064', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092856', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092752', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092700', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092674', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092661', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092657', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093112', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092895', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092787', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092726', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092696', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092683', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092670', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Thromboembolism', 'efo_term': 'Thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.320 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of optic neuritis? | In the context of optic neuritis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%optic neuritis%" OR LOWER(efo_term) LIKE "%optic neuritis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227776', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228631', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228916', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229201', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229771', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230056', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230341', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230911', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231196', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231481', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231766', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232336', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230626', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228346', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227206', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226636', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226351', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232051', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229486', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228061', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227491', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226921', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Optic Neuritis', 'efo_term': 'optic neuritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1516 | Q34 | What are the names of the genes that are targeted by the drug Azilsartan Kamedoxomil in the treatment of stroke? | In the context of stroke, the drug Azilsartan Kamedoxomil targets the gene angiotensin II receptor type 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%stroke%" OR LOWER(efo_term) LIKE "%stroke%") AND (LOWER(drugName) LIKE "%azilsartan kamedoxomil%" OR LOWER(tradeNames_list) LIKE "%azilsartan kamedoxomil%" OR LOWER(syns_list) LIKE "%azilsartan kamedoxomil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072676', 'drugName': 'Azilsartan Kamedoxomil', 'tradeNames_list': "['Edarbi']", 'syns_list': "['Azilsartan kamedoxomil', 'Azilsartan medoxomil potassium', 'TAK-491']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072668', 'drugName': 'Azilsartan Kamedoxomil', 'tradeNames_list': "['Edarbi']", 'syns_list': "['Azilsartan kamedoxomil', 'Azilsartan medoxomil potassium', 'TAK-491']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072666', 'drugName': 'Azilsartan Kamedoxomil', 'tradeNames_list': "['Edarbi']", 'syns_list': "['Azilsartan kamedoxomil', 'Azilsartan medoxomil potassium', 'TAK-491']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072672', 'drugName': 'Azilsartan Kamedoxomil', 'tradeNames_list': "['Edarbi']", 'syns_list': "['Azilsartan kamedoxomil', 'Azilsartan medoxomil potassium', 'TAK-491']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072674', 'drugName': 'Azilsartan Kamedoxomil', 'tradeNames_list': "['Edarbi']", 'syns_list': "['Azilsartan kamedoxomil', 'Azilsartan medoxomil potassium', 'TAK-491']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072670', 'drugName': 'Azilsartan Kamedoxomil', 'tradeNames_list': "['Edarbi']", 'syns_list': "['Azilsartan kamedoxomil', 'Azilsartan medoxomil potassium', 'TAK-491']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1959 | Q34 | What are the names of the genes that are targeted by the drug Vorapaxar Sulfate in the treatment of stroke? | In the context of stroke, the drug Vorapaxar Sulfate targets the gene coagulation factor II thrombin receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%stroke%" OR LOWER(efo_term) LIKE "%stroke%") AND (LOWER(drugName) LIKE "%vorapaxar sulfate%" OR LOWER(tradeNames_list) LIKE "%vorapaxar sulfate%" OR LOWER(syns_list) LIKE "%vorapaxar sulfate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193355', 'drugName': 'Vorapaxar Sulfate', 'tradeNames_list': "['Zontivity']", 'syns_list': "['SCH 530348', 'SCH-530348', 'Vorapaxar sulfate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2R', 'approvedName': 'coagulation factor II thrombin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1193359', 'drugName': 'Vorapaxar Sulfate', 'tradeNames_list': "['Zontivity']", 'syns_list': "['SCH 530348', 'SCH-530348', 'Vorapaxar sulfate']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'F2R', 'approvedName': 'coagulation factor II thrombin receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1716 | Q34 | What are the names of the genes that are targeted by the drug Ezetimibe in the treatment of Hypercholesterolemia? | In the context of Hypercholesterolemia, the drug Ezetimibe targets the gene NPC1 like intracellular cholesterol transporter 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypercholesterolemia%" OR LOWER(efo_term) LIKE "%hypercholesterolemia%") AND (LOWER(drugName) LIKE "%ezetimibe%" OR LOWER(tradeNames_list) LIKE "%ezetimibe%" OR LOWER(syns_list) LIKE "%ezetimibe%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097348', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097369', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097387', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097389', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097408', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097410', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097411', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097368', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097345', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097326', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097324', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097390', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097366', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097347', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097327', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.169 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of ulcerative colitis? | In the context of ulcerative colitis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ulcerative colitis%" OR LOWER(efo_term) LIKE "%ulcerative colitis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218675', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219299', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219507', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219715', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220131', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220339', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220547', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220755', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219091', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218259', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217843', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217635', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219923', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218883', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218467', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218051', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.13 | Q34 | What are the names of the genes that are targeted by the drug Risperidone in the treatment of schizophrenia? | In the context of schizophrenia, the drug Risperidone targets the gene 5-hydroxytryptamine receptor 2C, dopamine receptor D2 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%schizophrenia%" OR LOWER(efo_term) LIKE "%schizophrenia%") AND (LOWER(drugName) LIKE "%risperidone%" OR LOWER(tradeNames_list) LIKE "%risperidone%" OR LOWER(syns_list) LIKE "%risperidone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_149658', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149757', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149790', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149823', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149889', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149922', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149955', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150021', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150054', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150087', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150120', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150186', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150219', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150252', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150285', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150318', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150351', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150384', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150417', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150450', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150483', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150549', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150582', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150615', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150648', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150681', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150747', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150780', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150813', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150846', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150879', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150912', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150945', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150978', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151011', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151044', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151077', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151110', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151143', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151176', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151209', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151242', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150516', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149988', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149724', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149592', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149526', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149493', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150714', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150153', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149856', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149691', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149625', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149559', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1907 | Q34 | What are the names of the genes that are targeted by the drug Bimatoprost in the treatment of hypotrichosis simplex? | In the context of hypotrichosis simplex, the drug Bimatoprost targets the gene prostaglandin F receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypotrichosis simplex%" OR LOWER(efo_term) LIKE "%hypotrichosis simplex%") AND (LOWER(drugName) LIKE "%bimatoprost%" OR LOWER(tradeNames_list) LIKE "%bimatoprost%" OR LOWER(syns_list) LIKE "%bimatoprost%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149178', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149205', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149214', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149223', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149241', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149250', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149259', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149277', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149286', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149295', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149304', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149322', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149331', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149340', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149349', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149358', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149367', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149376', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149385', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149394', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149403', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149268', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149196', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149160', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149142', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149133', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149313', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149232', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149187', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149169', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149151', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.173 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of pneumonia? | In the context of pneumonia, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pneumonia%" OR LOWER(efo_term) LIKE "%pneumonia%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_220135', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219942', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218887', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218263', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220551', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218278', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219927', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217639', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220759', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218070', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218902', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217847', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219511', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218679', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219318', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218471', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217862', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219526', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220343', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219095', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218486', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219734', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220150', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220566', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220774', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219719', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220358', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217654', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219303', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218055', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218694', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219110', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217526', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218566', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219814', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218774', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218150', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220230', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220438', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220022', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217734', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218982', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220646', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217942', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218358', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219190', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219398', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219606', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.654 | Q34 | What are the names of the genes that are targeted by the drug Desmopressin Acetate in the treatment of head injury? | In the context of head injury, the drug Desmopressin Acetate targets the gene arginine vasopressin receptor 2, arginine vasopressin receptor 1A and arginine vasopressin receptor 1B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%head injury%" OR LOWER(efo_term) LIKE "%head injury%") AND (LOWER(drugName) LIKE "%desmopressin acetate%" OR LOWER(tradeNames_list) LIKE "%desmopressin acetate%" OR LOWER(syns_list) LIKE "%desmopressin acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_694453', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694486', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694497', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694508', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694530', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694541', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694552', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694574', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694585', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694596', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694607', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694629', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694640', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694651', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694662', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694673', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694684', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694695', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694706', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694717', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694728', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694750', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694761', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694772', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694783', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694794', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694816', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694827', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694838', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694849', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694860', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694871', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694882', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694893', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694904', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694915', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694926', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694937', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694948', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694959', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694970', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694981', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694992', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695003', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695014', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695025', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695036', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695047', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695058', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695069', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695080', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694739', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694563', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694475', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694431', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694409', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694398', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694805', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694618', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694519', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694464', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694442', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694420', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Craniocerebral Trauma', 'efo_term': 'head injury', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1050 | Q34 | What are the names of the genes that are targeted by the drug Pemetrexed in the treatment of mesothelioma? | In the context of mesothelioma, the drug Pemetrexed targets the gene thymidylate synthetase, phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase and dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%mesothelioma%" OR LOWER(efo_term) LIKE "%mesothelioma%") AND (LOWER(drugName) LIKE "%pemetrexed%" OR LOWER(tradeNames_list) LIKE "%pemetrexed%" OR LOWER(syns_list) LIKE "%pemetrexed%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_919045', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918670', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918795', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918667', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918478', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918793', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918606', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918859', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918856', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918543', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919300', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919110', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918669', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919173', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918730', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918732', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918733', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918544', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918481', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918796', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919174', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918922', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918919', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918921', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919362', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918982', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918985', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919297', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919047', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919048', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919108', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919299', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919111', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919171', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919237', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919360', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919363', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918858', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918541', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919234', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918604', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918984', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918607', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919236', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918480', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918237', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918238', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918343', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918377', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918307', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918273', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918378', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918412', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918272', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918308', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918413', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918342', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.262 | Q34 | What are the names of the genes that are targeted by the drug Budesonide in the treatment of emphysema? | In the context of emphysema, the drug Budesonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%emphysema%" OR LOWER(efo_term) LIKE "%emphysema%") AND (LOWER(drugName) LIKE "%budesonide%" OR LOWER(tradeNames_list) LIKE "%budesonide%" OR LOWER(syns_list) LIKE "%budesonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222613', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222748', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222793', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222838', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222928', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222973', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223018', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223108', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223153', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223198', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223243', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223333', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223378', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223423', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223468', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223513', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223558', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223603', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223648', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223693', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223738', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223828', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223873', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223918', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223963', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224008', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224098', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224143', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224188', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224233', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224278', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224323', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224368', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224413', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224458', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224503', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224548', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224593', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224638', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224683', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224728', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224773', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224818', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224863', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224908', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224953', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224998', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225043', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225088', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225133', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225178', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225268', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225313', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225358', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225403', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225223', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223783', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222703', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222523', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222433', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222388', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223063', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224053', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223288', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222883', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222658', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222568', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222478', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1201 | Q34 | What are the names of the genes that are targeted by the drug Sotalol Hydrochloride in the treatment of Ventricular arrhythmia? | In the context of Ventricular arrhythmia, the drug Sotalol Hydrochloride targets the gene adrenoceptor beta 2, adrenoceptor beta 1 and potassium voltage-gated channel subfamily H member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ventricular arrhythmia%" OR LOWER(efo_term) LIKE "%ventricular arrhythmia%") AND (LOWER(drugName) LIKE "%sotalol hydrochloride%" OR LOWER(tradeNames_list) LIKE "%sotalol hydrochloride%" OR LOWER(syns_list) LIKE "%sotalol hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_936160', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'syns_list': "['DL-MJ-1999', 'Darob', 'MJ 1999', 'MJ-1999', 'NSC-337251', 'NSC-760358Sotalol hcl', 'Sotalol hydrochloride']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936169', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'syns_list': "['DL-MJ-1999', 'Darob', 'MJ 1999', 'MJ-1999', 'NSC-337251', 'NSC-760358Sotalol hcl', 'Sotalol hydrochloride']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_936172', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'syns_list': "['DL-MJ-1999', 'Darob', 'MJ 1999', 'MJ-1999', 'NSC-337251', 'NSC-760358Sotalol hcl', 'Sotalol hydrochloride']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_936175', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'syns_list': "['DL-MJ-1999', 'Darob', 'MJ 1999', 'MJ-1999', 'NSC-337251', 'NSC-760358Sotalol hcl', 'Sotalol hydrochloride']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_936181', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'syns_list': "['DL-MJ-1999', 'Darob', 'MJ 1999', 'MJ-1999', 'NSC-337251', 'NSC-760358Sotalol hcl', 'Sotalol hydrochloride']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}, {'UUID': 'DrugTargetsIndication121923_text_936184', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'syns_list': "['DL-MJ-1999', 'Darob', 'MJ 1999', 'MJ-1999', 'NSC-337251', 'NSC-760358Sotalol hcl', 'Sotalol hydrochloride']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}, {'UUID': 'DrugTargetsIndication121923_text_936187', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'syns_list': "['DL-MJ-1999', 'Darob', 'MJ 1999', 'MJ-1999', 'NSC-337251', 'NSC-760358Sotalol hcl', 'Sotalol hydrochloride']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}, {'UUID': 'DrugTargetsIndication121923_text_936193', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'syns_list': "['DL-MJ-1999', 'Darob', 'MJ 1999', 'MJ-1999', 'NSC-337251', 'NSC-760358Sotalol hcl', 'Sotalol hydrochloride']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}, {'UUID': 'DrugTargetsIndication121923_text_936196', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'syns_list': "['DL-MJ-1999', 'Darob', 'MJ 1999', 'MJ-1999', 'NSC-337251', 'NSC-760358Sotalol hcl', 'Sotalol hydrochloride']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}, {'UUID': 'DrugTargetsIndication121923_text_936190', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'syns_list': "['DL-MJ-1999', 'Darob', 'MJ 1999', 'MJ-1999', 'NSC-337251', 'NSC-760358Sotalol hcl', 'Sotalol hydrochloride']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}, {'UUID': 'DrugTargetsIndication121923_text_936166', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'syns_list': "['DL-MJ-1999', 'Darob', 'MJ 1999', 'MJ-1999', 'NSC-337251', 'NSC-760358Sotalol hcl', 'Sotalol hydrochloride']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_936148', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'syns_list': "['DL-MJ-1999', 'Darob', 'MJ 1999', 'MJ-1999', 'NSC-337251', 'NSC-760358Sotalol hcl', 'Sotalol hydrochloride']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936145', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'syns_list': "['DL-MJ-1999', 'Darob', 'MJ 1999', 'MJ-1999', 'NSC-337251', 'NSC-760358Sotalol hcl', 'Sotalol hydrochloride']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936154', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'syns_list': "['DL-MJ-1999', 'Darob', 'MJ 1999', 'MJ-1999', 'NSC-337251', 'NSC-760358Sotalol hcl', 'Sotalol hydrochloride']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936178', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'syns_list': "['DL-MJ-1999', 'Darob', 'MJ 1999', 'MJ-1999', 'NSC-337251', 'NSC-760358Sotalol hcl', 'Sotalol hydrochloride']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_936163', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'syns_list': "['DL-MJ-1999', 'Darob', 'MJ 1999', 'MJ-1999', 'NSC-337251', 'NSC-760358Sotalol hcl', 'Sotalol hydrochloride']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_936157', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'syns_list': "['DL-MJ-1999', 'Darob', 'MJ 1999', 'MJ-1999', 'NSC-337251', 'NSC-760358Sotalol hcl', 'Sotalol hydrochloride']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936151', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'syns_list': "['DL-MJ-1999', 'Darob', 'MJ 1999', 'MJ-1999', 'NSC-337251', 'NSC-760358Sotalol hcl', 'Sotalol hydrochloride']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1394 | Q34 | What are the names of the genes that are targeted by the drug Ponesimod in the treatment of immune system disease? | In the context of immune system disease, the drug Ponesimod targets the gene sphingosine-1-phosphate receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%immune system disease%" OR LOWER(efo_term) LIKE "%immune system disease%") AND (LOWER(drugName) LIKE "%ponesimod%" OR LOWER(tradeNames_list) LIKE "%ponesimod%" OR LOWER(syns_list) LIKE "%ponesimod%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1036650', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036659', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036662', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036665', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036671', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036674', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036677', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036683', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036686', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036689', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036692', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036698', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036701', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036704', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036707', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036710', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036713', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036716', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036719', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036722', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036725', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036731', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036734', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036737', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036740', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036743', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036749', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036752', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036755', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036758', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036761', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036764', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036767', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036770', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036773', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036776', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036779', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036782', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036728', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036680', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036656', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036644', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036638', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036635', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036746', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036695', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036668', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036653', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036647', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036641', 'drugName': 'Ponesimod', 'tradeNames_list': "['Ponvory']", 'syns_list': "['ACT-128800', 'Ponesimod']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.907 | Q34 | What are the names of the genes that are targeted by the drug Naproxen in the treatment of Dysmenorrhea? | In the context of Dysmenorrhea, the drug Naproxen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%dysmenorrhea%" OR LOWER(efo_term) LIKE "%dysmenorrhea%") AND (LOWER(drugName) LIKE "%naproxen%" OR LOWER(tradeNames_list) LIKE "%naproxen%" OR LOWER(syns_list) LIKE "%naproxen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838128', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838179', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838196', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838213', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838247', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838264', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838281', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838330', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838371', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838412', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838453', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838535', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838576', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838617', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838658', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838699', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838740', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838781', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838822', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838863', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838904', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838986', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839027', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839068', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839109', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839150', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839232', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839273', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839314', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839355', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839396', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839437', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839478', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839519', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839560', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839601', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839642', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839683', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838945', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838298', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838162', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838094', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838060', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838043', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839191', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838494', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838230', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838145', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838111', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838077', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.677 | Q34 | What are the names of the genes that are targeted by the drug Pemigatinib in the treatment of cholangiocarcinoma? | In the context of cholangiocarcinoma, the drug Pemigatinib targets the gene fibroblast growth factor receptor 1, fibroblast growth factor receptor 3 and fibroblast growth factor receptor 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cholangiocarcinoma%" OR LOWER(efo_term) LIKE "%cholangiocarcinoma%") AND (LOWER(drugName) LIKE "%pemigatinib%" OR LOWER(tradeNames_list) LIKE "%pemigatinib%" OR LOWER(syns_list) LIKE "%pemigatinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_706925', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706964', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706977', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706990', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707016', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707029', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707042', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707068', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707081', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707055', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_706951', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706873', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706860', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706899', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707003', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706938', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706912', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706886', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.260 | Q34 | What are the names of the genes that are targeted by the drug Budesonide in the treatment of chronic obstructive pulmonary disease? | In the context of chronic obstructive pulmonary disease, the drug Budesonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic obstructive pulmonary disease%" OR LOWER(efo_term) LIKE "%chronic obstructive pulmonary disease%") AND (LOWER(drugName) LIKE "%budesonide%" OR LOWER(tradeNames_list) LIKE "%budesonide%" OR LOWER(syns_list) LIKE "%budesonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222611', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222746', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222791', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222836', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222926', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222971', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223016', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223106', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223151', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223196', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223241', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223331', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223376', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223421', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223466', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223511', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223556', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223601', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223646', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223691', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223736', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223826', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223871', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223916', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223961', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224006', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224096', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224141', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224186', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224231', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224276', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224321', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224366', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224411', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224456', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224501', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224546', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224591', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224636', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224681', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224726', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224771', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224816', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224861', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224906', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224951', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224996', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225041', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225086', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225131', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225176', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225266', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225311', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225356', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225401', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225221', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223781', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222701', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222521', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222431', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222386', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223061', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224051', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223286', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222881', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222656', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222566', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222476', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.850 | Q34 | What are the names of the genes that are targeted by the drug Celecoxib in the treatment of spondylitis? | In the context of spondylitis, the drug Celecoxib targets the gene prostaglandin-endoperoxide synthase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%spondylitis%" OR LOWER(efo_term) LIKE "%spondylitis%") AND (LOWER(drugName) LIKE "%celecoxib%" OR LOWER(tradeNames_list) LIKE "%celecoxib%" OR LOWER(syns_list) LIKE "%celecoxib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_833170', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833388', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833392', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833499', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833281', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833059', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832948', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832944', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833503', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833277', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833166', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833055', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.873 | Q34 | What are the names of the genes that are targeted by the drug Diclofenac Sodium in the treatment of hemorrhage? | In the context of hemorrhage, the drug Diclofenac Sodium targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hemorrhage%" OR LOWER(efo_term) LIKE "%hemorrhage%") AND (LOWER(drugName) LIKE "%diclofenac sodium%" OR LOWER(tradeNames_list) LIKE "%diclofenac sodium%" OR LOWER(syns_list) LIKE "%diclofenac sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_836125', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836179', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836197', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836215', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836251', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836269', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836287', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836323', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836341', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836359', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836377', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836413', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836431', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836449', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836467', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836485', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836503', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836521', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836539', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836557', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836575', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836611', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836629', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836647', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836665', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836683', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836719', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836737', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836755', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836773', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836791', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836809', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836827', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836845', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836863', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836881', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836899', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836917', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836935', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836953', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836593', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836305', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836161', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836089', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836053', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836035', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836701', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836395', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836233', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836143', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836107', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836071', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1182 | Q34 | What are the names of the genes that are targeted by the drug Alogliptin Benzoate in the treatment of type 2 diabetes mellitus? | In the context of type 2 diabetes mellitus, the drug Alogliptin Benzoate targets the gene dipeptidyl peptidase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%type 2 diabetes mellitus%" OR LOWER(efo_term) LIKE "%type 2 diabetes mellitus%") AND (LOWER(drugName) LIKE "%alogliptin benzoate%" OR LOWER(tradeNames_list) LIKE "%alogliptin benzoate%" OR LOWER(syns_list) LIKE "%alogliptin benzoate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_933886', 'drugName': 'Alogliptin Benzoate', 'tradeNames_list': "['Nesina']", 'syns_list': "['Alogliptin (as benzoate)', 'Alogliptin benzoate', 'SYR 322', 'SYR-322']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933889', 'drugName': 'Alogliptin Benzoate', 'tradeNames_list': "['Nesina']", 'syns_list': "['Alogliptin (as benzoate)', 'Alogliptin benzoate', 'SYR 322', 'SYR-322']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933890', 'drugName': 'Alogliptin Benzoate', 'tradeNames_list': "['Nesina']", 'syns_list': "['Alogliptin (as benzoate)', 'Alogliptin benzoate', 'SYR 322', 'SYR-322']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933891', 'drugName': 'Alogliptin Benzoate', 'tradeNames_list': "['Nesina']", 'syns_list': "['Alogliptin (as benzoate)', 'Alogliptin benzoate', 'SYR 322', 'SYR-322']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933888', 'drugName': 'Alogliptin Benzoate', 'tradeNames_list': "['Nesina']", 'syns_list': "['Alogliptin (as benzoate)', 'Alogliptin benzoate', 'SYR 322', 'SYR-322']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933884', 'drugName': 'Alogliptin Benzoate', 'tradeNames_list': "['Nesina']", 'syns_list': "['Alogliptin (as benzoate)', 'Alogliptin benzoate', 'SYR 322', 'SYR-322']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933882', 'drugName': 'Alogliptin Benzoate', 'tradeNames_list': "['Nesina']", 'syns_list': "['Alogliptin (as benzoate)', 'Alogliptin benzoate', 'SYR 322', 'SYR-322']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933881', 'drugName': 'Alogliptin Benzoate', 'tradeNames_list': "['Nesina']", 'syns_list': "['Alogliptin (as benzoate)', 'Alogliptin benzoate', 'SYR 322', 'SYR-322']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933892', 'drugName': 'Alogliptin Benzoate', 'tradeNames_list': "['Nesina']", 'syns_list': "['Alogliptin (as benzoate)', 'Alogliptin benzoate', 'SYR 322', 'SYR-322']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933887', 'drugName': 'Alogliptin Benzoate', 'tradeNames_list': "['Nesina']", 'syns_list': "['Alogliptin (as benzoate)', 'Alogliptin benzoate', 'SYR 322', 'SYR-322']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933885', 'drugName': 'Alogliptin Benzoate', 'tradeNames_list': "['Nesina']", 'syns_list': "['Alogliptin (as benzoate)', 'Alogliptin benzoate', 'SYR 322', 'SYR-322']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933883', 'drugName': 'Alogliptin Benzoate', 'tradeNames_list': "['Nesina']", 'syns_list': "['Alogliptin (as benzoate)', 'Alogliptin benzoate', 'SYR 322', 'SYR-322']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.140 | Q34 | What are the names of the genes that are targeted by the drug Osimertinib in the treatment of cancer? | In the context of cancer, the drug Osimertinib targets the gene epidermal growth factor receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%osimertinib%" OR LOWER(tradeNames_list) LIKE "%osimertinib%" OR LOWER(syns_list) LIKE "%osimertinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217363', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217267', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217291', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217279', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217339', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217231', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217327', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217183', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217375', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217243', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217207', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217195', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217255', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217387', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217351', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217315', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217303', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217219', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217181', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217265', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217289', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217337', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217349', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217385', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217253', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217301', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217313', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217193', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217205', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217325', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217229', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217217', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217277', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217361', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217241', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217373', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217228', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217240', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217372', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217180', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217384', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217252', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217264', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217276', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217192', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217288', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217300', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217204', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217312', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217324', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217216', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217360', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217336', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217348', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217158', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217142', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217148', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217156', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217160', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217162', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217150', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217164', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217138', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217144', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217140', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217152', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217168', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217170', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217154', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217172', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217146', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217166', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.